Organic electroluminescent materials and devices

Abstract

The invention relates to organic electroluminescent materials and devices. The present invention provides a compound having a first ligand LA of Formula I. In Formula I, Part A and Part D are each independently a monocyclic or fused polycyclic system wherein each ring in the monocyclic or fused polycyclic system is independently a 5-to 10-membered carbocyclic or heterocyclic ring. And part C is a 5-membered or 6-membered carbocyclic or heterocyclic ring. At least one RC or RD is a substituent R * comprising a carbocyclic or heterocyclic group. The invention also provides formulations, OLEDs and consumer products containing the compounds.

Description

[0001] Cross-reference to related applications

[0002] This application is a continuation-in-part of co-pending U.S. Patent Application No. 18 / 814,301, filed August 23, 2024; co-pending U.S. Patent Application No. 19 / 176,025, filed April 10, 2025; and co-pending U.S. Patent Application No. 18 / 814,299, filed August 23, 2024. This application also claims priority under 35 U.S.SC §119(e) to U.S. Provisional Application No. 63 / 738,566, filed December 24, 2024; U.S. Provisional Application No. 63 / 795,731, filed April 28, 2025; U.S. Provisional Application No. 63 / 742,057, filed January 6, 2025; U.S. Provisional Application No. 63 / 678,268, filed August 1, 2024; U.S. Provisional Application No. 63 / 754,002, filed February 5, 2025; and U.S. Provisional Application No. 63 / 793,115, filed April 23, 2025, the entire contents of all of the foregoing applications are incorporated herein by reference. Technical Field

[0003] This disclosure generally relates to organic or metal coordination compounds and formulations and their various uses, including as emitters, sensitizers, charge transporters or exciton transporters in devices such as organic light-emitting diodes and related electronic devices and consumer products. Background Technology

[0004] For various reasons, optoelectronic devices utilizing organic materials are becoming increasingly popular. Many of the materials used to manufacture these devices are relatively inexpensive, thus organic optoelectronic devices have the potential to offer a cost advantage over inorganic devices. Furthermore, the inherent properties of organic materials, such as their flexibility, make them more suitable for specific applications, such as fabrication on flexible substrates. Examples of organic optoelectronic devices include organic light-emitting diodes / devices (OLEDs), organic phototransistors, organic photovoltaic cells, organic scintillators, and organic photodetectors. For OLEDs, organic materials can offer performance advantages over conventional materials.

[0005] OLEDs utilize organic thin films that emit light when a voltage is applied to the device. OLEDs are becoming an increasingly popular technology for applications such as displays, lighting, and backlighting.

[0006] One application of emitting molecules is in full-color displays. Industry standards for such displays require pixels suited to emitting specific colors (called "saturated" colors). Specifically, these standards require pixels saturated with red, green, and blue light. Alternatively, OLEDs can be designed to emit white light. In conventional liquid crystal displays, absorption filters are used to filter the emission from a white backlight to produce red, green, and blue emission. The same technology can be used for OLEDs. White OLEDs can be single-emitting-layer (EML) devices or stacked structures. Color can be measured using the CIE coordinate system, well-known in the field. Summary of the Invention

[0007] In one aspect, this disclosure provides a compound having a first ligand L A The compound comprises the structure of formula I:

[0008]

[0009] in:

[0010] Part A and part D are each independently a monocyclic or fused polycyclic system, wherein each ring in the monocyclic or fused polycyclic system is independently a 5- to 10-membered carbon ring or heterocyclic ring.

[0011] Some C atoms are 5- or 6-membered carbon rings or heterocycles;

[0012] Z 1 Z 2 and X 1 To X 4 Each of them is independently C or N;

[0013] Partial A-bond to X 1 To X 4 One of them, wherein X 1 To X 4 One of them is C;

[0014] Y is selected from the following groups: BR, BRR', NR, PR, P(O)R, O, S, Se, C=O, C=S, C=Se, C=NR', C=CRR', S=O, SO2, CR, CRR', SiRR' and GeRR';

[0015] K is selected from the following groups: direct key, O, S, N(R) α ), P(R α ), B(R) α ), C(R α (R) β ) and Si(R α (R) β );

[0016] R A R B R C and R D Each of these terms independently represents a single substitution up to the maximum amount of substitution or no substitution.

[0017] Each R, R', R α R β R A R B R C and R D Independently, it is hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, boroalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphinyl, selenyl and combinations thereof;

[0018] At least one R C Or R D It is a substituent R* containing a carbocyclic or heterocyclic group;

[0019] L A Coordination with metal M;

[0020] M is selected from the following groups: Ir, Rh, Re, Ru, Os, Pt, Pd, Ag, Au, and Cu;

[0021] M can coordinate with other ligands;

[0022] L A It can bind to other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands; and

[0023] Any two substituents can join or fuse to form a ring.

[0024] In another aspect, this disclosure provides a formulation of a compound having a first ligand L as described herein. A .

[0025] In another aspect, this disclosure provides an OLED having an organic layer, said organic layer comprising a first ligand L as described herein. A Compounds.

[0026] In another aspect, this disclosure provides a consumer product comprising an OLED having an organic layer, the organic layer comprising a first ligand L as described herein. A Compounds. Attached Figure Description

[0027] Figure 1 An organic light-emitting device is shown.

[0028] Figure 2 An inverted organic light-emitting device without an independent electron transport layer is demonstrated. Detailed Implementation

[0029] A. Terminology

[0030] Unless otherwise specified, the following terms as used herein are defined as follows:

[0031] As used herein, "top" means furthest from the substrate, and "bottom" means closest to the substrate. When the first layer is described as being "placed" "above" the second layer, the first layer is placed further away from the substrate. Unless specified that the first layer "contacts" the second layer, other layers may exist between the first and second layers. For example, even if various organic layers exist between the cathode and anode, the cathode may still be described as being "placed" "above" the anode.

[0032] As used herein, “solution-handleable” means capable of dissolving, dispersing or transporting in and / or depositing from a liquid medium in the form of a solution or suspension.

[0033] As used herein, and as will generally be understood by those skilled in the art, if the first energy level is closer to the vacuum level, then the first "Highest Occupied Molecular Orbital" (HOMO) or "Lowest Unoccupied Molecular Orbital" (LUMO) level is "greater than" or "higher than" the second HOMO or LUMO level. Since the ionization potential (IP) is measured as a negative energy relative to the vacuum level, a higher HOMO level corresponds to an IP with a smaller absolute value (less negative IP). Similarly, a higher LUMO level corresponds to an electron affinity (EA) with a smaller absolute value (less negative EA). On a conventional energy level diagram with the vacuum level at the top, the LUMO levels of a material are higher than the HOMO levels of the same material. "Higher" HOMO or LUMO levels appear to be closer to the top of this diagram than "lower" HOMO or LUMO levels.

[0034] As used herein, and as will generally be understood by those skilled in the art, if the first work function has a higher absolute value, then the first work function is “greater” or “higher” than the second work function. This is because the work function is typically measured as a negative number relative to the vacuum level, meaning that the “higher” work function is more negative. On a conventional energy level diagram with the vacuum level at the top, the “higher” work function is illustrated as being farther from the vacuum level in the downward direction. Therefore, the definitions of HOMO and LUMO levels follow different rules than those for the work function.

[0035] This document may describe light emission regions by referring to the color of the light emitted by layers, materials, areas, and devices. Generally, as used herein, an emitting region that produces a particular color of light may include one or more emitting layers arranged in a stacked manner on top of each other.

[0036] As used herein, “NIR,” “red,” “green,” “blue,” and “yellow” layers, materials, regions, or devices refer to layers, materials, regions, or devices that emit light in the wavelength ranges of approximately 700–1500 nm, 580–700 nm, 500–600 nm, 400–500 nm, and 540–600 nm, respectively, or layers, materials, regions, or devices that have the highest emission spectral peak in the corresponding wavelength regions. In some arrangements, individual regions, layers, materials, or devices may provide separate “deep blue” and “light blue” emissions. As used herein, a “deep blue” emission component refers to an emission whose peak emission wavelength is at least approximately 4 nm smaller than the peak emission wavelength of the “light blue” emission component. Typically, the peak emission wavelength of the “light blue” emission component is in the range of approximately 465–500 nm, and the peak emission wavelength of the “deep blue” emission component is in the range of approximately 400–470 nm, but these ranges may vary for some configurations.

[0037] In some arrangements, a color-changing layer is provided that converts, modifies, or alters the color of light emitted by another layer to emit light with a different wavelength. This color-changing layer can be tuned to shift the wavelength of light emitted by the other layer by a defined amount, such as by the difference between the wavelength of the emitted light and the wavelength of the resulting light. Generally, there are two types of color-changing layers: color filters that modify the spectrum by removing light of unwanted wavelengths, and color-changing layers that convert higher-energy photons into lower-energy ones. For example, a "red" filter may be present to filter input light to remove light with wavelengths outside the range of approximately 580-700 nm. The component of "color" refers to the component of light that produces or otherwise emits a specific color as described above when activated or used. For example, "a first emission region of a first color" and "a second emission region of a second color different from the first color" describe two emission regions that emit two different colors as described above when activated within the device.

[0038] As used herein, the light initially generated by a material, layer, or region is the exact opposite of the light ultimately emitted by the same or different structures, allowing the emitting materials, layers, and regions to be distinguished from each other and from other structures. Initial light generation is typically a result of energy level changes that lead to photon emission. For example, an organic emitting material may initially produce blue light, which can be converted into red or green light by a color filter, quantum dot, or other structure, causing the entire emitting stack or subpixel to emit red or green light. In this case, the initial emitting material, region, or layer may be referred to as the "blue" component, even if the subpixel is the "red" or "green" component.

[0039] In some cases, the color of components, such as the color of emitting regions, subpixels, color-changing layers, etc., can preferably be described according to 1931 CIE coordinates. For example, a yellow emitting material may have multiple peak emission wavelengths, one in or near the edge of the "green" region and one in or near the edge of the "red" region, as previously described. Therefore, as used herein, each color item also corresponds to a shape in the 1931 CIE coordinate color space. The shape in the 1931 CIE color space is constructed by tracing the trajectory between two color points and any other interior points. For example, the interior shape parameters for red, green, blue, and yellow can be defined as follows:

[0040]

[0041] The terms “halogen,” “halogen,” and “halogen group” are used interchangeably and refer to fluorine, chlorine, bromine, and iodine.

[0042] The term "acyl" refers to a substituted carbonyl group (-C(O)-R). s ).

[0043] The term "ester" refers to a substituted oxycarbonyl group (-OC(O)-R). s or -C(O)-OR s ) group.

[0044] The term "ether" refers to -OR s Group.

[0045] The terms "thio-" or "thioether" are used interchangeably and refer to -SR s Group.

[0046] The term "selenyl" refers to -SeR s Group.

[0047] The term "sulfinyl" refers to -S(O)-R s Group.

[0048] The term "sulfonyl" refers to -SO2-Rs Group.

[0049] The term "phosphono" refers to a group containing at least one phosphorus atom bonded to the relevant structure. Common examples of phosphono groups include, but are not limited to, -P(R) s )2 group or -PO(R s )2 groups, wherein each R s They can be the same or different.

[0050] The term "silyl group" refers to a group containing at least one silicon atom bonded to the relevant structure. Common examples of silyl groups include, but are not limited to, -Si(R s )3 groups, wherein each R s They can be the same or different.

[0051] The term "germanium alkyl" refers to a group containing at least one germanium atom bonded to the relevant structure. Common examples of germanium alkyl groups include, but are not limited to, -Ge(R s )3 groups, wherein each R s They can be the same or different.

[0052] The term "boronyl" refers to a group containing at least one boron atom bonded to the relevant structure. Common examples of boronyl groups include, but are not limited to, -B(R s )2 group or its Lewis adduct -B(R s )3 groups, of which R s They can be the same or different.

[0053] In each of the above, R s It can be hydrogen or a substituent selected from the group of general substituents as defined in this application. Preferred R s Selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, and combinations thereof. More preferably, R s Choose from the following groups: alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.

[0054] The term "alkyl" refers to and includes both straight-chain and branched alkyl groups having alkyl carbon atoms bonded to the relevant structure. Preferred alkyl groups are those containing one to fifteen carbon atoms, preferably one to nine carbon atoms, and preferred alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1,3-dimethylpropyl, 1,1-dimethylpropyl, 2-ethylpropyl, 1,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 3,3-dimethylpentyl, 3-ethylpentyl, 2,2,3-trimethylbutyl, etc. In addition, alkyl groups can be further substituted.

[0055] The term "cycloalkyl" refers to and includes monocyclic, polycyclic, and spirocyclic alkyl groups having cycloalkyl carbon atoms bonded to the relevant structure. Preferred cycloalkyl groups are those containing 3 to 12 cyclocarbon atoms and include cyclopropyl, cyclopentyl, cyclohexyl, bicyclo[3.1.1]heptyl, spiro[4.5]decyl, spiro[5.5]undecyl, adamantyl, etc. Furthermore, the cycloalkyl group may be further substituted.

[0056] The terms "heteroalkyl" or "heterocyclic alkyl" refer to an alkyl or cycloalkyl group having at least one carbon atom substituted with a heteroatom. Optionally, the at least one heteroatom is selected from O, S, N, P, B, Si, Ge, and Se, preferably O, S, or N. Furthermore, the heteroalkyl or heterocyclic alkyl group may be further substituted.

[0057] The term "alkenyl" refers to and includes both straight-chain and branched olefin groups. An alkenyl is essentially an alkyl group comprising at least one carbon-carbon double bond in an alkyl chain, wherein one carbon atom originates from a carbon-carbon double bond bonded to the associated structure. A cycloalkenyl is essentially a cycloalkyl group comprising at least one carbon-carbon double bond in a cycloalkyl ring. As used herein, the term "heteroalkenyl" refers to an alkenyl group having at least one carbon atom substituted by a heteroatom. Optionally, the at least one heteroatom is selected from O, S, N, P, B, Si, Ge, and Se, preferably O, S, or N. Preferred alkenyl, cycloalkenyl, or heteroalkenyl groups are those containing two to fifteen carbon atoms. Furthermore, alkenyl, cycloalkenyl, or heteroalkenyl groups may be further substituted.

[0058] The term "alkynyl" refers to and includes both straight-chain and branched alkyne groups. An alkynyl group is essentially an alkyl group comprising at least one carbon-carbon triple bond in an alkyl chain, where one carbon atom originates from a carbon-carbon triple bond bonded to the relevant structure. Preferred alkynyl groups are those containing two to fifteen carbon atoms. Furthermore, the alkynyl group may be further substituted.

[0059] The terms "aralkyl" or "arylalkyl" are used interchangeably and refer to an aryl-substituted alkyl group having an alkyl carbon atom bonded to the relevant structure. Furthermore, aralkyl groups can be further substituted.

[0060] The term "heterocyclic group" refers to and includes aromatic and non-aromatic cyclic groups containing at least one heteroatom. Optionally, the at least one heteroatom is selected from O, S, Se, N, P, B, Si, Ge, and Se, preferably O, S, N, or B. The terms "heteroaromatic cyclic group" and "heteroaryl group" are used interchangeably. Preferred non-aromatic heterocyclic groups are those containing 3 to 10 ring atoms, preferably those containing 3 to 7 ring atoms including at least one heteroatom, and include cyclic amines such as morpholino, piperidinyl, pyrrolyl, etc., and cyclic ethers / thioethers such as tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, etc. Furthermore, the heterocyclic group may be further substituted or fused.

[0061] The term "aryl" refers to and includes both monocyclic and polycyclic aromatic hydrocarbon groups. Polycyclic groups may have two or more rings, wherein two carbons are common to two adjacent rings (the rings are "fused"). Preferred aryl groups are those containing six to thirty carbon atoms, more preferably six to twenty-four carbon atoms, six to eighteen carbon atoms, and more preferably six to twelve carbon atoms. Particularly preferred are aryl groups having six, ten, twelve, fourteen, or eighteen carbon atoms. Suitable aryl groups include phenyl, biphenyl, terphenyl, triphenylene, tetraphenylene, naphthalene, anthracene, phenanthrene, pyrene, etc. Perylene and azulene, preferably phenyl, biphenyl, biphenylene, triphenylene, and naphthalene. Additionally, the aryl group may be further substituted or fused, such as, but not limited to, fluorene.

[0062] The term "heteroaryl" refers to and includes both monocyclic aromatic groups and polycyclic aromatic ring systems having at least one heteroatom. Heteroatoms include, but are not limited to, O, S, Se, N, P, B, Si, Ge, and Se. In many cases, O, S, N, or B are preferred heteroatoms. Monocyclic heteroaromatic systems are preferably monocyclic rings having 5 or 6 ring atoms, and the rings may have one to six heteroatoms. Polycyclic heterocyclic systems may have two or more aromatic rings, wherein two atoms are common to two adjacent rings (the rings are "fused"), and at least one of the rings is a heteroaryl. Polycyclic heteroaromatic ring systems may have one to six heteroatoms in each ring. Preferred heteroaryls are those containing three to thirty carbon atoms, preferably three to twenty-four carbon atoms, three to eighteen carbon atoms, and more preferably three to twelve carbon atoms. Suitable heteroaryl groups include dibenzothiophene, dibenzofuran, dibenzoselenene, furan, thiophene, benzofuran, benzothiophene, benzoselenene, carbazole, indolocarbazole, pyridylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxtriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxthiazine, oxadiazine, indole, benzimidazole, Indazole, indoxazine, benzoxazole, benzoisoxazole, benzothiazole, quinoline, isoquinoline, cinnamoline, quinazoline, quinoxaline, naphthidine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuranopyridine, furanodipyridine, benzothiophenopyridine, thiophenodipyridine, benzoselenophenopyridine, selenophenodipyridine, aziborane, cycloborane, 5λ 2 ,9λ 2 -diaza-13b-boronanaphene[2,3,4-de]anthracene, 5λ 2 -Benzo[d]benzo[4,5]imidazo[3,2-a]imidazolium and 5,9-dioxa-13b-boronazona[3,2,1-de]anthracene; preferably dibenzothiophene, dibenzofuran, dibenzoselenophene, carbazole, indolocarbazole, imidazolium, pyridine, triazine, benzimidazole, 5λ 2 ,9λ 2 -diaza-13b-boronanaphene[2,3,4-de]anthracene, 5λ 2 -Benzo[d]benzo[4,5]imidazo[3,2-a]imidazo[3,2-a]imidazo[3,2,1-de]anthracene. Additionally, heteroaryl groups can be further substituted or fused.

[0063] Among the aryl and heteroaryl groups listed above, triphenylene, naphthalene, anthracene, dibenzothiophene, dibenzofuran, dibenzoselenene, carbazole, indolocarbazole, imidazole, pyridine, pyrazine, pyrimidine, triazine, benzimidazole, and 5λ are included. 2 ,9λ 2-diaza-13b-boronanaphene[2,3,4-de]anthracene, 5λ 2 -Benzo[d]benzo[4,5]imidazo[3,2-a]imidazo, 5,9-dioxa-13b-boronazona[3,2,1-de]anthracene groups, and their corresponding aza analogs are of particular interest.

[0064] In many cases, the general substituents are selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, boranalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, selenyl, sulfinyl, sulfonyl, phosphin, and combinations thereof.

[0065] In some cases, preferred general substituents are selected from the group consisting of: deuterium, fluorine, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, boroalkyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thioyl, and combinations thereof.

[0066] In some cases, more preferred general substituents are selected from the group consisting of: deuterium, fluorine, alkyl, cycloalkyl, alkoxy, aryloxy, amino, silyl, germanyl, boronyl, aryl, heteroaryl, nitrile, thio, and combinations thereof.

[0067] In some cases, even more preferred general substituents are selected from the group consisting of: deuterium, fluorine, alkyl, cycloalkyl, silyl, aryl, heteroaryl, nitriles and combinations thereof.

[0068] In other cases, the most preferred general substituent is selected from the group consisting of: deuterium, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.

[0069] With one or more substituents (e.g., R, R' ... A R A R 1 Where no specific definition is provided for (e.g., R1, etc.), each of the one or more substituents shall be understood to independently represent hydrogen or a substituent selected from the group consisting of general substituents as defined herein. Similarly, each of the one or more substituents may optionally be coupled or fused with another substituent to form a ring. It should also be understood that any substituent that may be selected from general substituents as defined herein may also be selected from preferred general substituents as defined herein, more preferred general substituents as defined herein, even more preferred general substituents as defined herein, or most preferred general substituents as defined herein.

[0070] The terms "substituted" and "substituted" refer to substituents other than H being bonded to the relevant position, such as carbon or nitrogen. For example, when R... 1 When representing monosubstitution, then an R 1 It must not be H (i.e., substitution). Similarly, when R 1 When representing disubstituted substitution, then the two Rs 1 It must not be H. Similarly, when R... 1 When R represents zero or no substitution, 1 For example, it could be hydrogen atoms with all available valences in the ring atom, such as carbon atoms in benzene and nitrogen atoms in pyrrole, or simply none for ring atoms with fully saturated valences, such as nitrogen atoms in pyridine. The maximum possible number of substitutions in a ring structure will depend on the total number of available valences in the ring atoms.

[0071] As used herein, “combination thereof” means that one or more members of the applicable list are combined to form a known or chemically stable arrangement that can be conceived by one of ordinary skill in the art from the applicable list. For example, alkyl and deuterium can be combined to form partially or fully deuterated alkyl groups; halogen and alkyl groups can be combined to form haloalkyl substituents; and halogen, alkyl, and aryl groups can be combined to form haloaralkyl groups. In one instance, the term substitution includes a combination of two to four listed groups. In another instance, the term substitution includes a combination of two to three groups. In yet another instance, the term substitution includes a combination of two groups. Preferred combinations of substituents are combinations containing up to fifty atoms that are not hydrogen or deuterium, or combinations containing up to forty atoms that are not hydrogen or deuterium, or combinations containing up to thirty atoms that are not hydrogen or deuterium. In many cases, preferred combinations of substituents will include up to twenty atoms that are not hydrogen or deuterium.

[0072] The term "aza" in the phrases used herein, namely aza-dibenzofuran, aza-dibenzothiophene, etc., refers to the substitution of one or more CH groups in the corresponding aromatic ring by a nitrogen atom. For example, and without limitation, azatriphenylene covers dibenzo[f,h]quinoxaline and dibenzo[f,h]quinoline. Other nitrogen analogs of the aza-derived compounds described above will be readily contemplated by those skilled in the art, and all such analogs are intended to be covered by the terminology set forth herein.

[0073] This disclosure includes all compounds of this disclosure with acceptable isotopic labeling, wherein one or more atoms are replaced by atoms having the same atomic number but with atomic masses or mass numbers different from those normally found in nature.

[0074] Examples of isotopes suitable for inclusion in compounds of this disclosure include isotopes of hydrogen, such as... 2 H and 3 H; isotopes of carbon, such as11 C 13 C and 14 C; isotopes of chlorine, such as 36 Cl; isotopes of fluorine, such as 18 F; Isotopes of iodine, such as 123 I, 124 I and 125 I; Isotopes of nitrogen, such as 13 N and 15 N; isotopes of oxygen, such as 15 O、 17 O and 18 O; isotopes of phosphorus, such as 32 P; and isotopes of sulfur, such as 35 S.

[0075] Certain isotope-labeled compounds disclosed herein, such as compounds doped with radioactive isotopes, can be used for diagnostics and other research. Radioactive isotope tritium (i.e., 3 H) and carbon-14 (i.e. 14 C) are particularly suitable for this purpose because they are easy to incorporate and easy to detect.

[0076] Using heavier isotopes such as deuterium (i.e. 2 H) substitution can provide certain advantages resulting from higher stability, and may therefore be preferred in some cases.

[0077] The isotopically labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by methods similar to those described in the appended examples and preparations, using appropriate isotopically labeled reagents instead of previously used unlabeled reagents.

[0078] For example, deuterated compounds can be readily prepared using methods known in the art. For instance, U.S. Patent No. 8,557,400, Patent Publication No. WO 2006 / 095951, and U.S. Patent Application Publication No. US2011 / 0037057 (which are incorporated herein by reference in their entirety) describe the preparation of deuterated organometallic complexes. Further references to Ming Yan et al., Tetrahedron 2015, 71, 1425–30, and Atzrodt et al., Angewandte Chemie Int. Ed. (Review) 2007, 46, 7744–65 (which are incorporated herein by reference in their entirety) describe efficient pathways for the deuteration of methylene hydrogen in benzylamines and the replacement of aromatic cyclic hydrogens with deuterium, respectively.

[0079] As used herein, any specifically listed substituent, such as, but not limited to, methyl, phenyl, pyridyl, etc., includes its undeuterated, partially deuterated, and fully deuterated forms. Similarly, substituents, such as, but not limited to, alkyl, aryl, cycloalkyl, heteroaryl, etc., also include their undeuterated, partially deuterated, and fully deuterated forms. Unless otherwise specified, atoms in a chemical structure that are not completely filled with H or D should be considered to include their undeuterated, partially deuterated, and fully deuterated forms. For example, chemical structures This refers to C6H6, C6D6, C6H3D3, and any other partially deuterated variants thereof. Some common basic partially or fully deuterated groups include, but are not limited to, CD3, CD2C(CH3)3, C(CD3)3, and C6D5. Similarly, in cases where the partially or fully defined atomic structure shows that a particular position can be deuterated, the same atomic structure in which one, two, or at most all deuterated atoms are replaced by hydrogen is also envisioned.

[0080] It should be understood that when a molecular fragment is described as a substituent or additionally linked to another part, its name can be written as if it were a fragment (e.g., phenyl, phenylene, naphthyl, dibenzofuranyl) or as if it were a whole molecule (e.g., benzene, naphthalene, dibenzofuran). As used herein, these different ways of naming substituents or linked fragments are considered equivalent.

[0081] In some cases, a pair of substituents in a molecule may join or fuse to form a ring. Preferred rings are five- to nine-membered carbon rings or heterocycles, including both cases where the ring formed by the pair of substituents is partially saturated and partially unsaturated. In other instances, a pair of adjacent substituents may join or fuse to form a ring. As used herein, “adjacent” means that the two substituents involved may be adjacent to each other on the same ring, or on two neighboring rings having two closest available substituted positions (such as the 2, 2' positions in biphenyl or the 1, 8 positions in naphthalene).

[0082] B. Compounds disclosed herein

[0083] In one aspect, this disclosure provides a compound having a first ligand L A The compound comprises the structure of formula I:

[0084]

[0085] in:

[0086] Part A and part D are each independently a monocyclic or fused polycyclic system, wherein each ring in the monocyclic or fused polycyclic system is independently a 5- to 10-membered carbon ring or heterocyclic ring.

[0087] Some C atoms are 5- or 6-membered carbon rings or heterocycles;

[0088] Z 1 Z 2 and X 1 To X 4 Each of them is independently C or N;

[0089] Partial A-bond to X 1 To X 4 One of them, wherein X 1 To X 4 One of them is C;

[0090] Y is selected from the following groups: BR, BRR', NR, PR, P(O)R, O, S, Se, C=O, C=S, C=Se, C=NR', C=CRR', S=O, SO2, CR, CRR', SiRR' and GeRR';

[0091] K is selected from the following groups: direct key, O, S, N(R) α ), P(R α ), B(R) α ), C(R α (R) β ) and Si(R α (R) β );

[0092] R A R B R C and R D Each of these terms independently represents a single substitution up to the maximum amount of substitution or no substitution.

[0093] Each R, R', R α R β R A R B R C and R D Independently, it is hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, boroalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphinyl, selenyl and combinations thereof;

[0094] At least one R C Or R D It is a substituent R* containing a carbocyclic or heterocyclic group;

[0095] L A Coordination with metal M;

[0096] M is selected from the following groups: Ir, Rh, Re, Ru, Os, Pt, Pd, Ag, Au, and Cu;

[0097] M can coordinate with other ligands;

[0098] L A It can bind to other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands; and

[0099] Any two substituents can join or fuse to form a ring.

[0100] Despite Z 1 -Z 2 The bonds between them are shown as single bonds, but it should be understood that they can be any other bonds necessary to manufacture the applicable ring-shaped portion of the part. This also applies to any other generalized ring or partial structure disclosed herein.

[0101] In some embodiments, the compound consists essentially of Formula I. In some embodiments, the compound has the structure of Formula I.

[0102] In some embodiments, if part C is a 6-membered ring and R C Or R D If it is R*, then the R* is not an unsubstituted phenyl or a phenyl substituted with an electron-withdrawing group.

[0103] In some embodiments, if portion C and portion D together form a naphthalene ring and R C If it is R*, then the R * Not unsubstituted carbazole, 2,7-di-tert-butylcarbazole, or 3,5-di-tert-butylcarbazole. In some embodiments, portion C and portion D together form a naphthalene ring and R C It is R*, and the R * Not unsubstituted carbazole, 2,7-di-tert-butyl-carbazole or 3,5-di-tert-butyl-carbazole.

[0104] In some embodiments, if R D If it is R*, then R* is not selected from the following list RD: In some embodiments, R D It is R*, and said R* is not selected from the list RD as defined herein.

[0105] In some embodiments, each R, R', R α R β R A R B R C and R DIndependently, it is hydrogen or a substituent selected from the group of preferred general substituents as defined herein. In some embodiments, each R, R', R α R β R A R B R C and R D Substituents that are independently hydrogen or selected from the group consisting of more preferred general substituents as defined herein. In some embodiments, each R, R', R α R β R A R B R C and R D Substituents that are independently hydrogen or selected from the group consisting of even more preferred general substituents as defined herein. In some embodiments, each R, R', R α R β R A R B R C and R D Substituents that are independently hydrogen or selected from the group of most preferred general substituents as defined herein.

[0106] In some embodiments, at least one R A R B R C Or R D Selected from the group consisting of universal substituents as defined herein. In some embodiments, at least one R A Selected from the group consisting of universal substituents as defined herein. In some embodiments, at least one R B Selected from the group consisting of universal substituents as defined herein. In some embodiments, at least one R C Selected from the group consisting of universal substituents as defined herein. In some embodiments, at least one R D Selected from the group consisting of universal substituents as defined herein. In some embodiments, at least one R A R B R C Or R D Choose from the group of preferred general substituents as defined herein.

[0107] In some embodiments of Formula I, at least one R, R', R α R β R A R B R C Or R DIt is partially or fully deuterated. In some embodiments, at least one R A It is partially or fully deuterated. In some embodiments, at least one R B It is partially or fully deuterated. In some embodiments, at least one R C It is partially or fully deuterated. In some embodiments, R D It is partially or fully deuterated. In some embodiments, at least one of R or R' is partially or fully deuterated. In some embodiments, R α Or R β At least one of them is partially or completely deuterated.

[0108] In some embodiments, R, R', R α R β R A R B R C and R D Each of them is independently hydrogen or a substituent selected from the group consisting of: deuterium, fluorine, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, boroalkyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, and combinations thereof.

[0109] In some embodiments, each of portions A and D is independently selected from the group consisting of the following list of cyclic portions: benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, triazole, cyclopentadiene, selenophene, naphthalene, quinoline, isoquinoline, quinazoline, benzofuran, aza-benzofuran, phenanthro[3,2-b]benzofuran, benzoxazole, aza-benzoxazole, benzothiophene, aza-benzene The following are listed: thiophene, benzothiazole, aza-benzothiazole, benzoselenene, aza-benzoselenene, indene, aza-indene, indole, aza-indole, benzimidazole, aza-benzimidazole, benzobenzimidazole, aza-benzimidazole, carbazole, aza-carbazole, naphtho-imidazolium, dibenzofuran, aza-dibenzofuran, dibenzothiophene, aza-dibenzothiophene, quinoxaline, phthalazine, phenanthrene, aza-phenanthrene, anthracene, aza-anthracene, phenanthridine, fluorene, and aza-fluorene. In some embodiments, the aza variant includes at least one N atom on the fused benzene ring.

[0110] In some embodiments, part A is a single ring.

[0111] In some embodiments, part A is selected from the group consisting of: benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, and triazole.

[0112] In some embodiments, portion A is benzene, pyrimidine, or pyridine. In some embodiments, portion A is benzene. In some embodiments, portion A is pyrimidine. In some embodiments, portion A is pyridine.

[0113] In some embodiments, part A is a multi-ring fused ring system.

[0114] In some embodiments, part A is selected from the group consisting of: naphthalene, quinoline, isoquinoline, quinazoline, benzofuran, azira-benzofuran, phenanthrene[3,2-b]benzofuran, benzoxazole, azira-benzoxazole, benzothiophene, azira-benzothiophene, benzothiazole, azira-benzothiazole, benzoselenophene, azira-benzoselenophene, indene, azira-indene, indole, azira-indole, benzimidazole, azira-benzimidazole, benzobenzimidazole, azira-benzimidazole, carbazole, azira-carbazole, naphtho-imidazolium, dibenzofuran, azira-dibenzofuran, dibenzothiophene, azira-dibenzothiazole, quinoxaline, phthalazine, phenanthrene, azira-phenanthrene, anthracene, azira-anthracene, phenanthridine, fluorene, and azira-fluorene.

[0115] In some embodiments, portion A is naphthalene or isoquinoline. In some embodiments, portion A is naphthalene. In some embodiments, portion A is isoquinoline.

[0116] In some embodiments, part D is a single ring.

[0117] In some embodiments, part D is selected from the group consisting of: benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, and triazole.

[0118] In some embodiments, part D is benzene, pyridine, oxazole, furan, thiazole, or imidazole. In some embodiments, part D is benzene. In some embodiments, part D is pyridine. In some embodiments, part D is oxazole. In some embodiments, part D is furan. In some embodiments, part D is thiazole. In some embodiments, part D is imidazole.

[0119] In some implementations, part D is a multi-ring fused ring system.

[0120] In some embodiments, part D comprises exactly two fused rings.

[0121] In some embodiments, part D comprises at least three fused rings.

[0122] In some embodiments, part D includes at least one 5-membered ring and at least one 6-membered ring.

[0123] In some embodiments, part D comprises at least two 6-membered rings.

[0124] In some embodiments, part D is selected from the group consisting of: naphthalene, quinoline, isoquinoline, quinazoline, benzofuran, aza-benzofuran, phenanthrene[3,2-b]benzofuran, benzoxazole, aza-benzoxazole, benzothiophene, aza-benzothiophene, benzothiazole, aza-benzothiazole, benzoselenophene, aza-benzoselenophene, indene, aza-indene, indole, aza-indole, benzimidazole, aza-benzimidazole, carbazole, aza-carbazole, naphthoimidazole, dibenzofuran, aza-dibenzofuran, dibenzothiphene, aza-dibenzothiphene, quinoxaline, phthalazine, phenanthrene, aza-phenanthrene, anthracene, aza-anthracene, phenanthridine, fluorene, and aza-fluorene. In some embodiments, part D comprises a 5-membered ring fused with part C.

[0125] In some embodiments, fraction D comprises benzofuran, benzothiophene, indole, or benzoselenene. In some embodiments, fraction D is benzofuran. In some embodiments, fraction D is benzothiophene. In some embodiments, fraction D is indole. In some embodiments, fraction D is benzoselenene.

[0126] In some embodiments, part D is naphthalene or quinoline. In some embodiments, part D is naphthalene. In some embodiments, part D is quinoline.

[0127] In some embodiments, each of portions A and D is independently a monocyclic or polycyclic fused ring system, wherein each ring in the monocyclic or polycyclic fused ring system is independently a 5- or 6-membered carbon ring or heterocyclic ring.

[0128] In some embodiments, each of portions A and D is independently a monocyclic or polycyclic fused ring system, wherein each ring in the monocyclic or polycyclic fused ring system is independently a 5- or 6-membered aryl or heteroaryl ring.

[0129] In some embodiments, at least one of portions A and D may be an independent polycyclic fused ring structure. In some embodiments, at least one of portions A and D may be an independent polycyclic fused ring structure comprising at least two fused rings. In some embodiments, the polycyclic fused ring structure has one 6-membered ring and one 5-membered ring. In some such embodiments, the 5-membered ring or the 6-membered ring may be coordinated with a metal. In some embodiments, the polycyclic fused ring structure has two 6-membered rings. In some embodiments, at least one of portions A and D may be independently selected from the group consisting of benzofuran, benzothiophene, benzoselenene, naphthalene, and their nitrogen heteromorphs.

[0130] In some embodiments, at least one of portions A and D may independently be a polycyclic fused ring structure comprising at least three fused rings. In some embodiments, the polycyclic fused ring structure has two 6-membered rings and one 5-membered ring. In some such embodiments, the 5-membered ring is fused with a ring coordinated to metal M, and the second 6-membered ring is fused with the 5-membered ring. In some embodiments, at least one of portions A and D may independently be selected from the group consisting of dibenzofuran, dibenzothiophene, dibenzoselenene, and their nitrogen heteromorphs. In some such embodiments, at least one of portions A and D may independently be further substituted at the ortho or meta position of the O, S, or Se atom with a substituent selected from the group consisting of deuterium, fluorine, nitriles, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof. In some such embodiments, the nitrogen heteromorph contains exactly one N atom at the 6-position (ortho to O, S, or Se) and a substituent at the 7-position (meta to O, S, or Se).

[0131] In some embodiments, at least one of portions A and D may independently be a polycyclic fused ring structure comprising at least four fused rings. In some embodiments, the polycyclic fused ring structure comprises three 6-membered rings and one 5-membered ring. In some such embodiments, the 5-membered ring is fused with a ring coordinated to metal M, the second 6-membered ring is fused with the 5-membered ring, and the third 6-membered ring is fused with the second 6-membered ring. In some such embodiments, the third 6-membered ring is further substituted with a substituent selected from the group consisting of: deuterium, fluorine, nitriles, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.

[0132] In some embodiments, at least one of portions A and D may independently be a polycyclic fused-ring structure comprising at least five fused rings. In some embodiments, the polycyclic fused-ring structure comprises four 6-membered rings and one 5-membered ring, or three 6-membered rings and two 5-membered rings. In some embodiments comprising two 5-membered rings, the 5-membered rings are fused together. In some embodiments comprising two 5-membered rings, the 5-membered rings are separated by at least one 6-membered ring. In some embodiments having one 5-membered ring, the 5-membered ring is fused with a ring coordinated to metal M, a second 6-membered ring is fused with the 5-membered ring, a third 6-membered ring is fused with the second 6-membered ring, and a fourth 6-membered ring is fused with the third 6-membered ring.

[0133] In some embodiments, at least one of portions A and D may independently be a nitride form of the polycyclic fused ring described above. In some such embodiments, at least one of portions A and D may independently contain exactly one nitride N atom. In some such embodiments, at least one of portions A and D contains exactly two nitride N atoms, which may be in one ring or in two different rings. In some such embodiments, the ring having the nitride N atom is separated from the metal M atom by at least two other rings. In some such embodiments, the ring having the nitride N atom is separated from the metal M atom by at least three other rings. In some such embodiments, each of the adjacent positions of the nitride N atom is substituted. In some embodiments, portion C is a 5-membered ring. In some embodiments, portion C is a 5-membered aromatic ring. In some embodiments, portion C is a 5-membered non-aromatic ring.

[0134] In some embodiments, part C is a 6-membered ring. In some embodiments, part C is a 6-membered aromatic ring. In some embodiments, part C is a 6-membered non-aromatic ring.

[0135] In some embodiments, fraction C is cyclopentadiene, furan, thiophene, pyrrole, or selenophene. In some embodiments, fraction C is cyclopentadiene. In some embodiments, fraction C is furan. In some embodiments, fraction C is thiophene. In some embodiments, fraction C is pyrrole. In some embodiments, fraction C is selenophene.

[0136] In some embodiments, portion C is benzene, pyridine, pyridazine, or pyrazine. In some embodiments, portion C is benzene. In some embodiments, portion C is pyridine. In some embodiments, portion C is pyridazine. In some embodiments, portion C is pyrazine.

[0137] In some embodiments, part C is a 5- or 6-membered aryl or heteroaryl ring.

[0138] In some embodiments, Z 1 It is N, and Z 2 It is C. In some embodiments, Z 1 It is C, and Z 2 It is N.

[0139] In some embodiments, Z 1 and Z 2 Each of them is N.

[0140] In some embodiments, Z 1 and Z 2 Each of them is C.

[0141] In some embodiments, X 1 To X 4 Each of them is C.

[0142] In some embodiments, X 1 To X 4 At least one of them is N. In some embodiments, X 1 To X 4 One of them is N.

[0143] In some embodiments, X 1 It is N. In some embodiments, X 2 It is N. In some embodiments, X 3 It is N. In some embodiments, X 4 It is N.

[0144] In some embodiments, Y is selected from the group consisting of O, S, and Se.

[0145] In some embodiments, Y is O.

[0146] In some embodiments, Y is selected from the group consisting of BR, NR, and PR.

[0147] In some embodiments, Y is selected from the group consisting of BRR', CRR', SiRR', GeRR' and PRR'.

[0148] In some embodiments, Y is selected from the group consisting of P(O)R, C=O, C=S, C=Se, C=NR, C=CRR', S=O and SO2.

[0149] In some embodiments, Y is CR.

[0150] In some embodiments, K is a direct key.

[0151] In some embodiments, K is O or S.

[0152] In some embodiments, K is O.

[0153] In some embodiments, K is N(R) α ), P(R α ) or B(R α ).

[0154] In some embodiments, K is C(R) α (R) β ) or Si(R α (R) β ).

[0155] In some embodiments, the compound comprises an electron-withdrawing group. In some embodiments, the Hammett constant of the electron-withdrawing group is greater than 0. In some embodiments, the Hammett constant of the electron-withdrawing group is equal to or greater than 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, or 1.1.

[0156] In some embodiments, the first ligand L A Electron-withdrawing groups selected from the following EWG1 list: F, CF3, CN, COCH3, CHO, COCF3, COOMe, COOCF3, NO2, SF3, SiF3, PF4, SF5, OCF3, SCF3, SeCF3, SOCF3, SeOCF3, SO2F, SO2CF3, SeO2CF3, OSeO2CF3, OCN, SCN, SeCN, NC. + N(R k2 )3、(R k2 )2CCN、(R k2 )2CCF3、CNC(CF3)2、BR k3 R k2 Substituted or unsubstituted dibenzoboranecyclopentadiene, 1-substituted carbazole, 1,9-substituted carbazole, substituted or unsubstituted carbazole, substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyridoxine, substituted or unsubstituted triazine, substituted or unsubstituted oxazole, substituted or unsubstituted benzoxazole, substituted or unsubstituted thiazole, substituted or unsubstituted benzothiazole, substituted or unsubstituted imidazole, substituted or unsubstituted benzimidazole, ketones, carboxylic acids, esters, nitriles, isonitriles, sulfinyl groups, sulfonyl groups, partially and fully fluorinated alkyl groups, partially and fully fluorinated aryl groups, partially and fully fluorinated heteroaryl groups, cyano-containing alkyl groups, cyano-containing aryl groups, cyano-containing heteroaryl groups, isocyanates,

[0157]

[0158] Each R k1 Indicates single substitution up to the maximum permissible substitution or no substitution;

[0159] Where Y G Choose from the following groups: BR e NR e PR e ,O,S,Se,C=O,S=O,SO2,CR e Rf SiR e R f and GeR e R f' ;and

[0160] Where R k1 R k2 R k3 R e and R f Each of them is independently hydrogen or a substituent selected from the group of universal substituents defined herein.

[0161] In some embodiments, the first ligand L A Includes electron-withdrawing groups from the group consisting of structures selected from the following EWG2 list:

[0162]

[0163]

[0164] In some embodiments, the first ligand L A Includes electron-withdrawing groups from the group consisting of structures selected from the following EWG3 list:

[0165] In some embodiments, the first ligand L A Includes electron-withdrawing groups from the group consisting of structures selected from the following EWG4 list:

[0166] In some embodiments, the first ligand L A Electron-withdrawing groups that are π-electron-deficient and consist of structures selected from the following π-EWG lists: CN, COCH3, CHO, COCF3, COOMe, COOCF3, NO2, SF3, SiF3, PF4, SF5, OCF3, SCF3, SeCF3, SOCF3, SeOCF3, SO2F, SO2CF3, SeO2CF3, OSeO2CF3, OCN, SCN, SeCN, NC. + N(R k2 3. BR k2 R k3Substituted or unsubstituted dibenzoboranecyclopentadiene, 1-substituted carbazole, 1,9-substituted carbazole, substituted or unsubstituted carbazole, substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyridazine, substituted or unsubstituted triazine, substituted or unsubstituted oxazole, substituted or unsubstituted benzoxazole, substituted or unsubstituted thiazole, substituted or unsubstituted benzothiazole, substituted or unsubstituted imidazole, substituted or unsubstituted benzimidazole, ketones, carboxylic acids, esters, nitriles, isonitriles, sulfinyl groups, sulfonyl groups, partially and fully fluorinated aryl groups, partially and fully fluorinated heteroaryl groups, cyano-containing aryl groups, cyano-containing heteroaryl groups, isocyanates,

[0167] The variables are the same as those previously defined.

[0168] In some embodiments, at least one R A Not hydrogen. In some embodiments, at least two R... A It's not hydrogen.

[0169] In some embodiments, at least one R A It contains at least one carbon atom. In some embodiments, at least one R A It contains at least two carbon atoms. In some embodiments, at least one R A It contains at least three carbon atoms. In some embodiments, at least one R A It contains at least four carbon atoms. In some embodiments, at least two R atoms are present. A It independently contains at least one carbon atom.

[0170] In some embodiments, at least one R A It includes substituents selected from the group consisting of: alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof. In some embodiments, at least two R... A Independently comprising substituents selected from the group consisting of: alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof. In some embodiments, at least two R A It is an alkyl group.

[0171] In some embodiments, two R A Joined or fused to form an annular portion A2. In some embodiments, the annular portion A2 is selected from the group consisting of a list of annular portions as defined herein.

[0172] In some embodiments, each RB It is H.

[0173] In some embodiments, at least one R B It's not hydrogen.

[0174] In some embodiments, at least one R B It contains at least one carbon atom. In some embodiments, at least one R B It contains at least two carbon atoms. In some embodiments, at least one R B It contains at least three carbon atoms. In some embodiments, at least one R B It contains at least four carbon atoms.

[0175] In some embodiments, at least one R B It includes substituents selected from the group consisting of: alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof.

[0176] In some embodiments, two R B Joined or fused to form an annular portion B2. In some embodiments, the annular portion B2 is selected from the group consisting of a list of annular portions as defined herein.

[0177] In some embodiments, at least one R C It's not hydrogen.

[0178] In some embodiments, at least one R C It contains at least one carbon atom. In some embodiments, at least one R C It contains at least two carbon atoms. In some embodiments, at least one R C It contains at least three carbon atoms. In some embodiments, at least one R C It contains at least four carbon atoms.

[0179] In some embodiments, at least one R C It includes substituents selected from the group consisting of: alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof.

[0180] In some embodiments, at least one R C It is a substituent R*. In some embodiments, at least one R C It is a substituent R*, and the substituent R* contains a substituted aryl or heteroaryl group.

[0181] In some embodiments, at least one R C It is a substituent R*, and the substituent R* includes formula II. The structure, wherein:

[0182] Ring F is a 5- to 10-membered carbon ring or heterocyclic ring;

[0183] R F Indicates monosubstituted to trisubstituted or unsubstituted;

[0184] Each R 1' R 2' and R F Independently, it is hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, boranalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphinyl, selenyl and combinations thereof; and

[0185] Where R 1' Or R 2' At least one of them is not hydrogen or deuterium.

[0186] In some embodiments, ring F is a 5- or 6-membered carbocyclic ring or a heterocyclic ring. In some embodiments, ring F is a 5- or 6-membered aryl or heteroaryl ring.

[0187] In some embodiments, at least one R F It is or contains an electron-withdrawing group from the EWG1 list as defined herein. In some embodiments, at least one R F It is or contains an electron-withdrawing group from the EWG2 list as defined herein. In some embodiments, at least one R F It is or contains an electron-withdrawing group from the EWG3 list as defined herein. In some embodiments, at least one R F It is or contains an electron-withdrawing group from the EWG4 list as defined herein. In some embodiments, at least one R F It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0188] In some embodiments, R 1' and R 2' Neither of them are hydrogen or deuterium.

[0189] In some embodiments, R 1' and R 2' Each of them is independently selected from the group consisting of: alkyl, cycloalkyl, aryl, heteroaryl, silalkyl, germanalkyl, and combinations thereof.

[0190] In some embodiments, R 1' and R 2' They are the same. In some embodiments, R 1' and R 2' They are different.

[0191] In some embodiments, R 1' and R 2' Each of them contains at least one carbon atom. In some embodiments, R 1' and R 2' Each of them contains at least two carbon atoms. In some embodiments, R 1' and R 2' Each of them contains at least three carbon atoms. In some embodiments, R 1' and R 2' Each of them contains at least four carbon atoms. In some embodiments, R 1' and R 2' Each of them contains at least five carbon atoms.

[0192] In some embodiments, at least one R F It is neither hydrogen nor deuterium.

[0193] In some embodiments, at least one R F Choose from the following groups: alkyl, cycloalkyl, aryl, heteroaryl, silalkyl, germanalkyl, and combinations thereof.

[0194] In some embodiments, ring F is selected from the group consisting of: benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, imidazole-derived carbene, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, and triazole.

[0195] In some embodiments, at least one R C It is a substituent R*, and the substituent R* includes formula IIA. The structure, where X 1a X 2a and X 3a Each of them is either C or N.

[0196] In some embodiments, the key to X 2a R F Selected from the group consisting of: alkyl, cycloalkyl, aryl, heteroaryl, silyl, germanyl, and combinations thereof. In some embodiments, bonded to X 2a R F It is an alkyl group. In some embodiments, it is bonded to X. 2a R F It is aryl or heteroaryl. In some embodiments, it is bonded to X. 2a R F It is a silane. In some embodiments, it is bonded to X. 2a R F It is a germanyl group.

[0197] In some embodiments, X 1a X 2aand X 3a Each of them is C. In some embodiments, X 1a X 2a and X 3a At least one of them is N. In some embodiments, X 1a X 2a and X 3a One of them is N.

[0198] In some embodiments, R F It is aryl. In some embodiments, R F It is benzene.

[0199] In some embodiments, the substituent R* is a monocyclic or polycyclic fused ring system, wherein each ring of the monocyclic or polycyclic fused ring system is independently a 5- to 10-membered carbon ring or heterocyclic ring.

[0200] In some embodiments, the substituent R* comprises a cyclic moiety selected from the group consisting of the following cyclic moiety list 2: benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, triazole, cyclopentadiene, selenophene, selenoazole, tellurazole, naphthalene, anthracene, phenanthrene, quinoline, isoquinoline, quinazoline, benzofuran, aza-benzofuran, phenanthrene[3,2-b]benzofuran, benzoxazole, aza-benzoxazole, benzothiophene, aza-benzothiophene, benzothiazole, aza-benzothiazole, benzoselenene, aza-benzoselenene, indole, aza-indole, indole, aza-indole Indole, benzimidazole, azir-benzimidazole, benzothiophene, benzotelurophene, benzogermole, benzotellurazole, benzooxazole, benzothiazole, benzoselenazole, carbazole, azir-carbazole, naphtha-imidazole, dibenzofuran, azir-dibenzofuran, dibenzothiophene, azir-dibenzothiophene, quinoxaline, phthalazine, phenanthrene, azir-phenanthrene, anthracene, azir-anthracene, phenanthridine, fluorene, azir-fluorene, dibenzoselenene, dibenzotellurene, dibenzothiophene, and dibenzogermole.

[0201] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is a monocyclic ring.

[0202] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is a substituted phenyl group, wherein the substituted phenyl group does not contain an electron-withdrawing group.

[0203] In some embodiments, at least one R CIt is a substituent R*, and the substituent R* is a substituted or unsubstituted biphenyl, or a substituted or unsubstituted terphenyl.

[0204] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is selected from the group consisting of: substituted or unsubstituted oxazoles, substituted or unsubstituted thiazoles, substituted or unsubstituted selenoazoles, substituted or unsubstituted tellurazoles and substituted or unsubstituted imidazoles.

[0205] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is selected from the group consisting of: substituted or unsubstituted furans, substituted or unsubstituted thiophenes, substituted or unsubstituted selenophenes, substituted or unsubstituted tellurene, and substituted or unsubstituted pyrroles.

[0206] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is a polycyclic system.

[0207] In some embodiments, at least one R C It is a substituent R*, and the substituent R* contains at least two substituents of ring C' that are joined or fused to form a polycyclic system.

[0208] In some embodiments, ring C' is a saturated ring. In some embodiments, ring C' is a 5-membered saturated ring. In some embodiments, ring C' is a 6-membered saturated ring.

[0209] In some embodiments, at least one R C It is a substituent R*, and the substituent R* further comprises at least two substituents of the ring C” that are joined or fused to form a polycyclic system.

[0210] In some embodiments, ring C” is a saturated ring. In some embodiments, ring C” is a saturated ring. In some embodiments, ring C” is a 5-membered saturated ring. In some embodiments, ring C” is a 6-membered saturated ring.

[0211] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is a fused aryl group.

[0212] In some embodiments, at least one R C The substituent R* is selected from the group consisting of substituted or unsubstituted naphthalene, substituted or unsubstituted anthracene, and substituted or unsubstituted phenanthrene. In some embodiments, the substituent R* is substituted or unsubstituted naphthalene. In some embodiments, at least one R as substituent R* CIt is anthracene, substituted or unsubstituted. In some embodiments, at least one R is a substituent R*. C It is either substituted or unsubstituted phytosanitary.

[0213] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is a fused heteroaryl group.

[0214] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is selected from the group consisting of: substituted or unsubstituted dibenzofuran, substituted or unsubstituted dibenzothiophene, substituted or unsubstituted carbazole, substituted or unsubstituted dibenzoselenophene, substituted or unsubstituted dibenzotellurphene, substituted or unsubstituted fluorene, substituted or unsubstituted dibenzothiophene, and substituted or unsubstituted dibenzogeranazole.

[0215] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is a substituted or unsubstituted dibenzofuran, or a substituted or unsubstituted carbazole. In some embodiments, the at least one R as substituent R* C It is a substituted or unsubstituted dibenzofuran. In some embodiments, at least one R as a substituent R* C It is either substituted or unsubstituted carbazole.

[0216] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is selected from the group consisting of: substituted or unsubstituted benzofuran, substituted or unsubstituted benzothiophene, substituted or unsubstituted benzoselenene, substituted or unsubstituted benzotellurene, substituted or unsubstituted indole, substituted or unsubstituted benzothiophene, substituted or unsubstituted benzogermanazole, and substituted or unsubstituted indole.

[0217] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is selected from the group consisting of: substituted or unsubstituted benzoxazole, substituted or unsubstituted benzothiazole, substituted or unsubstituted benzoselenazole, substituted or unsubstituted benzotelurazole, and substituted or unsubstituted benzoimidazole.

[0218] In some embodiments, at least one R C It is a substituent R*, and the substituent R* is deuterated. In some embodiments, at least one R C It is a substituent R*, and the substituent R* is not deuterated.

[0219] In some embodiments, two R C Joining or fusion to form a ring.

[0220] In some embodiments, at least one R D It's not hydrogen.

[0221] In some embodiments, at least one R D It contains at least one carbon atom. In some embodiments, at least one R D It contains at least two carbon atoms. In some embodiments, at least one R D It contains at least three carbon atoms. In some embodiments, at least one R D It contains at least four carbon atoms.

[0222] In some embodiments, at least one R D It includes substituents selected from the group consisting of: alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof.

[0223] In some embodiments, at least one R D It is a substituent R*.

[0224] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is a substituted aryl or heteroaryl group.

[0225] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is a substituted aryl or heteroaryl group.

[0226] In some embodiments, at least one R D It is a substituent R*, and the substituent R* includes formula II. The structure, wherein:

[0227] Ring F is a 5- to 10-membered carbon ring or heterocyclic ring;

[0228] R F Indicates monosubstituted to trisubstituted or unsubstituted;

[0229] Each R 1' R 2' and R F Independently, it is hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, boranalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphinyl, selenyl and combinations thereof; and

[0230] Where R1' Or R 2' At least one of them is not hydrogen or deuterium.

[0231] In some embodiments, ring F is a 5- or 6-membered carbocyclic ring or a heterocyclic ring. In some embodiments, ring F is a 5- or 6-membered aryl or heteroaryl ring.

[0232] In some embodiments, at least one R F It is or contains an electron-withdrawing group from the EWG1 list as defined herein. In some embodiments, at least one R F It is or contains an electron-withdrawing group from the EWG2 list as defined herein. In some embodiments, at least one R F It is or contains an electron-withdrawing group from the EWG3 list as defined herein. In some embodiments, at least one R F It is or contains an electron-withdrawing group from the EWG4 list as defined herein. In some embodiments, at least one R F It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0233] In some embodiments, R 1' and R 2' Neither of them are hydrogen or deuterium.

[0234] In some embodiments, R 1' and R 2' Each of them is independently selected from the group consisting of: alkyl, cycloalkyl, aryl, heteroaryl, silalkyl, germanalkyl, and combinations thereof.

[0235] In some embodiments, R 1' and R 2' They are the same. In some embodiments, R 1' and R 2' They are different.

[0236] In some embodiments, R 1' and R 2' Each of them contains at least one carbon atom. In some embodiments, R 1' and R 2' Each of them contains at least two carbon atoms. In some embodiments, R 1' and R 2' Each of them contains at least three carbon atoms. In some embodiments, R 1' and R 2' Each of them contains at least four carbon atoms. In some embodiments, R 1' and R 2' Each of them contains at least five carbon atoms.

[0237] In some embodiments, at least one R F It is neither hydrogen nor deuterium.

[0238] In some embodiments, at least one R F Choose from the following groups: alkyl, cycloalkyl, aryl, heteroaryl, silalkyl, germanalkyl, and combinations thereof.

[0239] In some embodiments, ring F is selected from the group consisting of: benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, imidazole-derived carbene, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, and triazole.

[0240] In some embodiments, at least one R D It is a substituent R*, and the substituent R* contains the structure of formula IIA.

[0241] Where X 1a X 2a and X 3a Each of them is either C or N.

[0242] In some embodiments, the key to X 2a R F Selected from the group consisting of: alkyl, cycloalkyl, aryl, heteroaryl, silyl, germanyl, and combinations thereof. In some embodiments, bonded to X 2a R F It is an alkyl group. In some embodiments, it is bonded to X. 2a R F It is aryl or heteroaryl. In some embodiments, it is bonded to X. 2a R F It is a silane. In some embodiments, it is bonded to X. 2a R F It is a germanyl group.

[0243] In some embodiments, X 1a X 2a and X 3a Each of them is C. In some embodiments, X 1a X 2a and X 3a At least one of them is N. In some embodiments, X 1a X 2a and X 3a One of them is N.

[0244] In some embodiments, R F It is aryl. In some embodiments, R F It is benzene.

[0245] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is a monocyclic or polycyclic fused ring system, wherein each ring in the monocyclic or polycyclic fused ring system is independently a 5- to 10-membered carbon ring or heterocyclic ring.

[0246] In some embodiments, at least one R D It is a substituent R*, and the substituent R* contains a cyclic portion selected from the group consisting of the following list 2 of cyclic portions as defined herein.

[0247] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is a monocyclic ring.

[0248] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is a substituted phenyl group.

[0249] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is a substituted or unsubstituted biphenyl, or a substituted or unsubstituted terphenyl.

[0250] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is selected from the group consisting of: substituted or unsubstituted oxazoles, substituted or unsubstituted thiazoles, substituted or unsubstituted selenoazoles, substituted or unsubstituted tellurazoles and substituted or unsubstituted imidazoles.

[0251] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is selected from the group consisting of: substituted or unsubstituted furans, substituted or unsubstituted thiophenes, substituted or unsubstituted selenophenes, substituted or unsubstituted tellurene, and substituted or unsubstituted pyrroles.

[0252] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is a polycyclic system.

[0253] In some embodiments, at least one R D It is a substituent R*, and the substituent R* contains at least two substituents of ring C' that are joined or fused to form a polycyclic system.

[0254] In some embodiments, ring C' is a saturated ring. In some embodiments, ring C' is a 5-membered saturated ring. In some embodiments, ring C' is a 6-membered saturated ring.

[0255] In some embodiments, at least one R DIt is a substituent R*, and the substituent R* further comprises at least two substituents of the ring C” that are joined or fused to form a polycyclic system.

[0256] In some embodiments, ring C” is a saturated ring. In some embodiments, ring C” is a saturated ring. In some embodiments, ring C” is a 5-membered saturated ring. In some embodiments, ring C” is a 6-membered saturated ring.

[0257] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is a fused aryl group.

[0258] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is selected from the group consisting of: substituted or unsubstituted naphthalene, substituted or unsubstituted anthracene, and substituted or unsubstituted phenanthrene. In some embodiments, at least one R as substituent R* D It is substituted or unsubstituted naphthalene. In some embodiments, at least one R is used as a substituent R*. D It is anthracene, substituted or unsubstituted. In some embodiments, at least one R is a substituent R*. D It is either substituted or unsubstituted phytosanitary.

[0259] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is a fused heteroaryl group.

[0260] In some embodiments, at least one R D The substituent R* is selected from the group consisting of: substituted or unsubstituted dibenzofuran, substituted or unsubstituted dibenzothiophene, substituted or unsubstituted carbazole, substituted or unsubstituted dibenzoselenophene, substituted or unsubstituted dibenzotellurphene, substituted or unsubstituted fluorene, substituted or unsubstituted dibenzothiophene, and substituted or unsubstituted dibenzogermanazole. In some embodiments, at least one R as substituent R* D It is either substituted or unsubstituted carbazole.

[0261] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is a substituted or unsubstituted dibenzofuran, or a substituted or unsubstituted carbazole. In some embodiments, the at least one R as substituent R* D It is a substituted or unsubstituted dibenzofuran. In some embodiments, at least one R is a substituent R*. D It is either substituted or unsubstituted carbazole.

[0262] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is selected from the group consisting of: substituted or unsubstituted benzofuran, substituted or unsubstituted benzothiophene, substituted or unsubstituted benzoselenene, substituted or unsubstituted benzotellurene, substituted or unsubstituted indole, substituted or unsubstituted benzothiophene, substituted or unsubstituted benzogermanazole, and substituted or unsubstituted indole.

[0263] In some embodiments, at least one R D It is a substituent R*, and the substituent R* is selected from the group consisting of: substituted or unsubstituted benzoxazole, substituted or unsubstituted benzothiazole, substituted or unsubstituted benzoselenazole, substituted or unsubstituted benzotellurazole and substituted or unsubstituted benzimidazole.

[0264] In some embodiments, at least one R D It is not deuterated.

[0265] In some embodiments, R D It is a substituent R*, and R* is not a partially or fully deuterated phenyl, a partially or fully deuterated biphenyl, a para-substituted fully deuterated phenyl, a fully deuterated thiophene, a neopentyl-substituted fully deuterated thiophene, or a fully deuterated 2-methylpyridine.

[0266] In some embodiments, at least two R D Joining or fusion to form a ring.

[0267] In some embodiments, at least one R α Or R β It's not hydrogen.

[0268] In some embodiments, at least one R α Or R β It contains at least one carbon atom. In some embodiments, at least one R α Or R β It contains at least two carbon atoms. In some embodiments, at least one R α Or R β It contains at least three carbon atoms. In some embodiments, at least one R α Or R β It contains at least four carbon atoms.

[0269] In some embodiments, at least one R α Or R β It includes substituents selected from the group consisting of: alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof.

[0270] In some embodiments, Rα and R β Joining or fusion to form a ring.

[0271] In some embodiments, at least one R or R' is not hydrogen.

[0272] In some embodiments, at least one R or R' contains at least one carbon atom. In some embodiments, at least one R or R' contains at least two carbon atoms. In some embodiments, at least one R or R' contains at least three carbon atoms. In some embodiments, at least one R or R' contains at least four carbon atoms.

[0273] In some embodiments, at least one R or R' comprises a substituent selected from the group consisting of alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof.

[0274] In some embodiments, R and R' are joined or fused to form a ring.

[0275] In some embodiments, portions C and D together do not form naphthalene.

[0276] In some embodiments, portions C and D together form naphthalene, and R C Not unsubstituted carbazole, 2,7-di-tert-butyl-carbazole or 3,5-di-tert-butyl-carbazole.

[0277] In some embodiments, Z 2 Bond to X 1 In some embodiments, Z 2 Bond to X 2 In some embodiments, Z 2 Bond to X 3 In some embodiments, Z 2 Bond to X 4 .

[0278] In some embodiments, the metal is Ir.

[0279] In some embodiments, the metal is Pt.

[0280] In some embodiments, the substituent R* is selected from the group consisting of the structures in List A below:

[0281]

[0282]

[0283]

[0284]

[0285]

[0286] Wherein (D)H indicates that the part can be H or D.

[0287] In some embodiments, ligand L A Select the group consisting of the structures listed in List 1 below:

[0288]

[0289]

[0290]

[0291]

[0292]

[0293]

[0294] in:

[0295] X1 to X6 and X8 to X 19 Each can be either C or N independently;

[0296] Y A Y B and Y C Each of the following groups is selected independently: BR e NR e PR e ,O,S,Se,C=O,S=O,SO2,CR e R f SiR e R f and GeR e R f ;

[0297] Each R A1 R B1 R B2 and R B3 Independently represents monosubstituted to the maximum possible number of substitutions or no substitution;

[0298] Each R A1 R B1 R B2 R B3 R e and R f Substituents that are independently hydrogen or selected from the group of universal substituents as defined herein;

[0299] Any two substituents can join or fused to form a ring; and

[0300] At least one R B2 Or R B3 It is a substituent R* that contains a carbocyclic group or a heterocyclic group.

[0301] In ligand L A In some embodiments selected from Listing 1, X 8 It is carbon and bonded to a 5- or 6-membered N-containing ring at the top. In some embodiments, X 9 It is carbon and bonded to a 5- or 6-membered N-containing ring at the top. In some embodiments, X 10 It is carbon and bonded to a 5- or 6-membered N-containing ring at the top. In some embodiments, X 11 It is carbon and is bonded to a 5- or 6-membered N-containing ring at the top.

[0302] In ligand L A Selected from some embodiments in Listing 1, X8 to X 19 One of them is C and is substituted with a group selected from the group consisting of structures as defined in List A herein. In some of such embodiments, X 13 It is C and is substituted by groups of structures selected from the group consisting of the structure listed in List A as defined herein.

[0303] In ligand L A In some embodiments selected from Listing 1, X9 is C and is composed of R containing at least one C atom. B1 Replacement. In some such embodiments, R B1 It contains at least two carbon atoms. In some such embodiments, R B1 It contains at least three carbon atoms. In some such embodiments, R B1 It contains at least four carbon atoms.

[0304] In ligand L A In some embodiments selected from Listing 1, X9 is C and is R that includes a portion selected from the group consisting of the following. B1 Substitution: alkyl, partially or fully deuterated alkyl, cycloalkyl, partially or fully deuterated cycloalkyl, ether and electron-withdrawing groups.

[0305] In ligand L A In some embodiments selected from Listing 1, X9 is C and is R that includes a portion selected from the group consisting of the following. B1 Substitution: alkyl, partially or fully deuterated alkyl, cycloalkyl, partially or fully deuterated cycloalkyl and ether.

[0306] In ligand L AIn some embodiments selected from Listing 1, X9 is C and is R that includes a portion selected from the group consisting of the following. B1 Substitutions: CH3, CD3, isopropyl, tert-butyl, partially or fully deuterated isopropyl, partially or fully deuterated neopentyl, cyclohexane, partially or fully deuterated cyclohexane, OCH3, and F.

[0307] In ligand L A In some embodiments selected from Listing 1, X9 is C and is R that includes a portion selected from the group consisting of the following. B1 Substitution: CH3, CD3, tert-butyl, fully deuterated tert-butyl, and F.

[0308] In ligand L A In some embodiments selected from Listing 1, X9 is C and is contained in R with an electron-withdrawing group. B1 replace.

[0309] In ligand L A In some embodiments selected from Listing 1, X9 is C and is R containing an electron-withdrawing group selected from the EWG1 list as defined herein. B1 replace.

[0310] In ligand L A In some embodiments selected from Listing 1, X9 is C and is R as or contains an electron-withdrawing group from the EWG1 list as defined herein. B1 Replacement. In some such embodiments, R B1 It is or contains electron-withdrawing groups from the EWG2 list as defined herein. In some such embodiments, R B1 It is or contains electron-withdrawing groups from the EWG3 list as defined herein. In some such embodiments, R B1 It is or contains electron-withdrawing groups from the EWG4 list as defined herein. In some embodiments, R B1 It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0311] In ligand L A In some embodiments selected from Listing 1, X9 is C and is used as R for F, CH3, CD3, or carbazole. B1 replace.

[0312] In ligand L A In some embodiments selected from Listing 1, X9 is C and is used as R for CN or CD3. B1 replace.

[0313] In ligand L A In some of the embodiments selected from Listing 1, X9 is C and is R as a partially or fully fluorinated alkyl group.B1 replace.

[0314] In ligand L A In some embodiments selected from Listing 1, X9 is C and is contained in R which is silyl or germanyl. B1 replace.

[0315] In ligand L A In some embodiments selected from Listing 1, X9 is C and can be selected from Listing B as defined herein by R. B1 replace.

[0316] In ligand L A In some embodiments selected from Listing 1, two R A1 The rings are joined to form a fused ring. In some such embodiments, the fused ring may be benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, imidazole-derived carbenes, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, or triazole. In some such embodiments, the fused ring may be benzene.

[0317] In some embodiments, Y A It is NR e In some such embodiments, R e It is or includes the structure of Formula II or Formula IIA. In such embodiments, all embodiments related to Formula II or Formula IIA can be applied equivalently. In some embodiments, Y B and Y C Each of them is an O.

[0318] In ligand L A Selected from some embodiments in Listing 1, Y A It can be NR e And R e You can select a group consisting of the following structures (List A2):

[0319]

[0320]

[0321]

[0322]

[0323] The dashed line is connected to N.

[0324] In ligand L AIn some embodiments selected from Listing 1, at least one R A1 R B1 R B2 Or R B3 The group consisting of substituents as defined herein is selected. In ligand L... A In some embodiments selected from Listing 1, at least one R A1 R B1 R B2 Or R B3 The group of preferred universal substituents as defined herein is selected. In ligand L A In some embodiments selected from Listing 1, at least one R A1 R B1 R B2 Or R B3 It is partially or fully deuterated. In some embodiments, at least one R A1 It is partially or fully deuterated. In some embodiments, at least one R B1 It is partially or fully deuterated. In some embodiments, at least one R B2 It is partially or fully deuterated. In some embodiments, at least one R B3 It is partially or completely deuterated.

[0325] In which ligand L A In some embodiments selected from Listing 1, at least one R A1 It is or contains an electron-withdrawing group from the EWG1 list as defined herein. In some embodiments, at least one R A1 It is or contains an electron-withdrawing group from the EWG2 list as defined herein. In some embodiments, at least one R A1 It is or contains an electron-withdrawing group from the EWG3 list as defined herein. In some embodiments, at least one R A1 It is or contains an electron-withdrawing group from the EWG4 list as defined herein. In some embodiments, at least one R A1 It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0326] In which ligand L A In some embodiments selected from Listing 1, at least one R B1 It is or contains an electron-withdrawing group from the EWG1 list as defined herein. In some embodiments, at least one R B1 It is or contains an electron-withdrawing group from the EWG2 list as defined herein. In some embodiments, at least one R B1 It is or contains an electron-withdrawing group from the EWG3 list as defined herein. In some embodiments, at least one R B1It is or contains an electron-withdrawing group from the EWG4 list as defined herein. In some embodiments, at least one R B1 It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0327] In which ligand L A In some embodiments selected from Listing 1, at least one R B2 It is or contains an electron-withdrawing group from the EWG1 list as defined herein. In some embodiments, at least one R B2 It is or contains an electron-withdrawing group from the EWG2 list as defined herein. In some embodiments, at least one R B2 It is or contains an electron-withdrawing group from the EWG3 list as defined herein. In some embodiments, at least one R B2 It is or contains an electron-withdrawing group from the EWG4 list as defined herein. In some embodiments, at least one R B2 It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0328] In which ligand L A In some embodiments selected from Listing 1, at least one R B3 It is or contains an electron-withdrawing group from the EWG1 list as defined herein. In some embodiments, at least one R B3 It is or contains an electron-withdrawing group from the EWG2 list as defined herein. In some embodiments, at least one R B3 It is or contains an electron-withdrawing group from the EWG3 list as defined herein. In some embodiments, at least one R B3 It is or contains an electron-withdrawing group from the EWG4 list as defined herein. In some embodiments, at least one R B3 It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0329] In some embodiments, ligand L A Select the group consisting of the structures listed in List 2 below:

[0330]

[0331]

[0332]

[0333]

[0334]

[0335]

[0336]

[0337] in:

[0338] X is C or N;

[0339] Y A Y B and Y C Each of the following groups is selected independently: BR e NR e PR e ,O,S,Se,C=O,S=O,SO2,CR e R f SiR e R f and GeR e R f ;

[0340] Each R A1 R B1 R B2 and R B3 Independently represents monosubstituted to the maximum possible number of substitutions or no substitution;

[0341] Each R A1 R B1 R B2 R B3 R e and R f Substituents that are independently hydrogen or selected from the group of universal substituents as defined herein;

[0342] Any two substituents can join or fused to form a ring; and

[0343] At least one R B2 Or R B3 It is a substituent R* that contains a carbocyclic group or a heterocyclic group.

[0344] In ligand L A Selected from some embodiments in Listing 2, two R A1 The rings are joined to form a fused ring. In some such embodiments, the fused ring may be benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, imidazole-derived carbenes, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, or triazole. In some such embodiments, the fused ring may be benzene.

[0345] In ligand L A In some embodiments selected from Listing 2, X is carbon and can be selected from the group consisting of structures in Listing A as defined herein. B2 replace.

[0346] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is R containing at least one C atom. B1 Replacement. In some such embodiments, R B1 It contains at least two carbon atoms. In some such embodiments, R B1 It contains at least three carbon atoms. In some such embodiments, R B1 It contains at least four carbon atoms.

[0347] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is included in the R portion selected from the group consisting of the following. B1 Substitution: alkyl, partially or fully deuterated alkyl, cycloalkyl, partially or fully deuterated cycloalkyl, ether and electron-withdrawing groups.

[0348] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is included in the R portion selected from the group consisting of the following. B1 Substitution: alkyl, partially or fully deuterated alkyl, cycloalkyl, partially or fully deuterated cycloalkyl and ether.

[0349] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is included in the R portion selected from the group consisting of the following. B1 Substitutions: CH3, CD3, isopropyl, tert-butyl, partially or fully deuterated isopropyl, partially or fully deuterated neopentyl, cyclohexane, partially or fully deuterated cyclohexane, OCH3, and F.

[0350] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is included in the R portion selected from the group consisting of the following. B1 Substitution: CH3, CD3, tert-butyl, fully deuterated tert-butyl, and F.

[0351] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is enclosed by an R containing an electron-withdrawing group. B1 replace.

[0352] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is an R group containing an electron-withdrawing group selected from the EWG1 list as defined herein. B1replace.

[0353] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is treated as or contains an electron-withdrawing group from the EWG1 list as defined herein. B1 Replacement. In some such embodiments, R B1 It is or contains electron-withdrawing groups from the EWG2 list as defined herein. In some such embodiments, R B1 It is or contains electron-withdrawing groups from the EWG3 list as defined herein. In some such embodiments, R B1 It is or contains electron-withdrawing groups from the EWG4 list as defined herein. In some such embodiments, R B1 It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0354] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is used as the R of F, CH3, CD3, or carbazole. B1 replace.

[0355] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is used as the R of CN or CD3. B1 replace.

[0356] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is used as R of a partially or fully fluorinated alkyl group. B1 replace.

[0357] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is encapsulated by an R-type alkyl group containing silyl or germanyl groups. B1 replace.

[0358] In ligand L A In some embodiments selected from Listing 2, the carbon atom located at the para position attached to the top N-containing carbon is selected from the R atoms in the list as defined herein. B1 replace.

[0359] In ligand L A Selected from some embodiments in Listing 2, Y A It is NR in the structure e In some such embodiments, R eIt is or includes a structure of Formula II or Formula IIA. In such embodiments, all related embodiments of Formula II or Formula IIA can be applied similarly. In some embodiments, X is C in the structure. In some embodiments, X is N in the structure. In some embodiments, Y B and Y C Each of them is an O in the structure.

[0360] In ligand L A Selected from some embodiments in Listing 2, Y A It can be NR e And R e You can choose a group consisting of structures as defined in List A2 of this document.

[0361] In ligand L A In some embodiments selected from Listing 2, at least one R A1 R B1 R B2 Or R B3 The group consisting of substituents as defined herein is selected. In ligand L... A In some embodiments selected from Listing 1, at least one R A1 R B1 R B2 Or R B3 The group of preferred universal substituents as defined herein is selected. In ligand L A In some embodiments selected from Listing 1, at least one R A1 R B1 R B2 Or R B3 It is partially or fully deuterated. In some embodiments, at least one R A1 It is partially or fully deuterated. In some embodiments, at least one R B1 It is partially or fully deuterated. In some embodiments, at least one R B2 It is partially or fully deuterated. In some embodiments, at least one R B3 It is partially or completely deuterated.

[0362] In which ligand L A In some embodiments selected from Listing 2, at least one R A1 It is or contains an electron-withdrawing group from the EWG1 list as defined herein. In some embodiments, at least one R A1 It is or contains an electron-withdrawing group from the EWG2 list as defined herein. In some embodiments, at least one R A1 It is or contains an electron-withdrawing group from the EWG3 list as defined herein. In some embodiments, at least one R A1It is or contains an electron-withdrawing group from the EWG4 list as defined herein. In some embodiments, at least one R A1 It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0363] In which ligand L A In some embodiments selected from Listing 2, at least one R B1 It is or contains an electron-withdrawing group from the EWG1 list as defined herein. In some embodiments, at least one R B1 It is or contains an electron-withdrawing group from the EWG2 list as defined herein. In some embodiments, at least one R B1 It is or contains an electron-withdrawing group from the EWG3 list as defined herein. In some embodiments, at least one R B1 It is or contains an electron-withdrawing group from the EWG4 list as defined herein. In some embodiments, at least one R B1 It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0364] In which ligand L A In some embodiments selected from Listing 2, at least one R B2 It is or contains an electron-withdrawing group from the EWG1 list as defined herein. In some embodiments, at least one R B2 It is or contains an electron-withdrawing group from the EWG2 list as defined herein. In some embodiments, at least one R B2 It is or contains an electron-withdrawing group from the EWG3 list as defined herein. In some embodiments, at least one R B2 It is or contains an electron-withdrawing group from the EWG4 list as defined herein. In some embodiments, at least one R B2 It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0365] In which ligand L A In some embodiments selected from Listing 2, at least one R B3 It is or contains an electron-withdrawing group from the EWG1 list as defined herein. In some embodiments, at least one R B3 It is or contains an electron-withdrawing group from the EWG2 list as defined herein. In some embodiments, at least one R B3 It is or contains an electron-withdrawing group from the EWG3 list as defined herein. In some embodiments, at least one R B3 It is or contains an electron-withdrawing group from the EWG4 list as defined herein. In some embodiments, at least one R B3It is or contains electron-withdrawing groups from the list of π-EWG as defined herein.

[0366] In some embodiments, ligand L A Selected from L Ai (R H (R) I (R) J (R) K (R) L L Ai' (R H (R) I (R) J (R) K' (R) L ) and L Ai” (R H (R) I (R) J (R) K” (R) L ), where i is an integer from 1 to 10, i' is an integer from 11 to 37, i” is an integer from 38 to 43, and R H R I R J and R K Each of these is independently selected from V1 to V192; R L Selected from O1 to O328; R K' Selected from V1 to V180; R K” Selected from V1 to V178; and L Ai (R H (R) I (R) J (R) K (R) L L Ai' (R H (R) I (R) J (R) K' (R) L ) and L Ai” (R H (R) I (R) J (R) K” (R) L Each of the following is defined in Listing 3:

[0367]

[0368]

[0369]

[0370]

[0371]

[0372] Where O1 to O328 are defined in Listing A as defined in this document;

[0373] V1 to V192 are defined in the following Listing B:

[0374]

[0375]

[0376]

[0377] In some embodiments, ligand L A Selected from L A'n (R H (R) I (R) J (R) K (R) L ) and L A'n' (R H (R) I (R) J (R) K (R) K” (R) L ), where n is an integer from 1 to 12, n' is an integer from 13 to 26, and R H R I R J and R K Each of these is independently selected from V1 to V192; R L Selected from O1 to O328; R K” Selected from V1 to V178; and L A'n (R H (R) I (R) J (R) K (R) L (Selected from L) A'1 (V1)(V1)(V1)(V1)(O1) to L A'12 (V192)(V192)(V192)(V192)(O328), and L A'n' (R H (R) I (R) J (R) K (R) K” (R) L (Selected from L)A'13 (V1)(V1)(V1)(V1)(V1)(O1) to L A'26 (V192)(V192)(V192)(V192)(V178)(O328), as defined in Listing 3a below:

[0378]

[0379]

[0380]

[0381] V1 to V192 are defined in List B as defined herein; and O1 to O328 are defined in List A as defined herein.

[0382] In some embodiments, the compound has the formula M(L) A ) p (L B ) q (L C ) r L B and L C Each is a bidentate ligand; and p is 1, 2 or 3; q is 0, 1 or 2; r is 0, 1 or 2; and p+q+r is the oxidation state of metal M.

[0383] In some embodiments, the compound has the formula selected from the group consisting of: Ir(L A 3. Ir(L) A (L) B )2、Ir(L A )2(L B ), Ir(L A )2(L C ) and Ir(L A (L) B (L) C ); and L A L B and L C They are different from each other.

[0384] In some embodiments, L B It is a substituted or unsubstituted phenylpyridine, and L C It is a substituted or unsubstituted acetylacetonate.

[0385] In some embodiments, the compound has the formula Pt(L) A (L) B ); and L A With L B They can be the same or different.

[0386] In some embodiments, L A With L B Connect to form a tetradentate ligand.

[0387] In some embodiments, L B and L C Each group is independently selected from the following groups, which are composed of structures listed in List 4:

[0388]

[0389]

[0390]

[0391] in:

[0392] T can be freely selected from the following groups: B, Al, Ga, and In;

[0393] K 1' Choose from the following groups: single bond, O, S, NR e PR e BR e CR e R f and SiR e R f ;

[0394] Y 1 To Y 13 Each of them is independently selected from the group consisting of C and N;

[0395] Y' selects from the following groups: BR e BR e R f NR e PR e P(O)R e O, S, Se, C=O

[0396] C = S, C = Se, C = NR e C = CR e R f S = O, SO2, CR e R f SiR e R f and GeR e R f ;

[0397] R e and R f They can be fused or joined to form rings;

[0398] Each R a R b R c and R d Independently represents single substitution up to the maximum permissible number of substitutions or no substitution;

[0399] R a1 R b1 R c1 R d1 R a R b R c R d R e and R f Each of these groups is independently hydrogen or a substituent selected from the group consisting of: deuterium, halogroup, alkyl, cycloalkyl, heteroalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, boranalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ester, nitrile, isonitrile, thio, selenalkyl, sulfinyl, sulfonyl, phosphinyl, and combinations thereof; and

[0400] R a1 R b1 R c1 R d1 R a R b R c and R d Any two substituents can fused or joined to form a ring or a polydentate ligand.

[0401] In some embodiments, L B and L C Each group is independently selected from the following groups, which are composed of structures listed in List 5:

[0402]

[0403]

[0404]

[0405]

[0406]

[0407]

[0408]

[0409] in:

[0410] Ra '、R b '、R c '、R d 'and R e Each can be used independently to indicate zero substitution, single substitution, or at most a maximum permissible number of substitutions to its associated ring;

[0411] R a1 R b1 R c1 R a '、R b '、R c '、R d 'and R e Each of these substituents is independently hydrogen or selected from the group consisting of: deuterium, halogroup, alkyl, cycloalkyl, heteroalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, boranalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ester, nitrile, isonitrile, thio, selenyl, sulfinyl, sulfonyl, phosphinyl, and combinations thereof; and

[0412] R a1 R b1 R c1 R a '、R b '、R c '、R d 'and R e The two substituents can fused or joined to form a ring or a polydentate ligand.

[0413] In some embodiments, L B Include The structure is such that the variables are the same as those previously defined. In some embodiments, Y 1 To Y 4 Each of them is independently carbon. In some embodiments, Y 1 To Y 4 At least one of them is N. In some embodiments, Y 1 To Y 4 One of them is N. In some embodiments, Y 1 It is N. In some embodiments, Y 2 It is N. In some embodiments, Y 3 It is N. In some embodiments, Y 4 It is N.

[0414] In some embodiments, Y 1 It is carbon and related to R a1 Connection. In some such embodiments, R a1It can be selected from the group consisting of the general substituents defined herein. In some such embodiments, R a1 The group consisting of preferred general substituents as defined herein can be selected. In some such embodiments, R a1 It is a tertiary alkyl, silyl, or germanyl group. In some such embodiments, R a1 It is a tertiary alkyl group. In some embodiments, Y 2 It is carbon and related to R a2 Connection. In some such embodiments, R a2 It can be selected from the group consisting of the general substituents defined herein. In some such embodiments, R a2 The group consisting of preferred general substituents as defined herein can be selected. In some such embodiments, R a2 It is a tertiary alkyl, silyl, or germanyl group. In some such embodiments, R a2 It is a tertiary alkyl group. In some embodiments, Y 3 It is carbon and R a3 Connection. In some such embodiments, R a3 It can be selected from the group consisting of the general substituents defined herein. In some such embodiments, R a3 The group consisting of preferred general substituents as defined herein can be selected. In some such embodiments, R a3 It is a tertiary alkyl, silyl, or germanyl group. In some such embodiments, R a3 It is a tertiary alkyl group. In some embodiments, Y 4 It is carbon and related to R a4 Connection. In some such embodiments, R a4 It can be selected from the group consisting of the general substituents defined herein. In some such embodiments, R a4 The group consisting of preferred general substituents as defined herein can be selected. In some such embodiments, R a4 It is a tertiary alkyl, silyl, or germanyl group. In some such embodiments, R a4 It is a tertiary alkyl group.

[0415] In some embodiments, Y 1 To Y 3 It is C, Y 4 It is N, and with Y 3 Connected R a3 It is a tertiary alkyl, silyl, or germanyl group. In some embodiments, Y 1 To Y 3 It is C, Y 4 It is N, and with Y 2 Connected R a2 It is a tertiary alkyl, silyl, or germanyl group.

[0416] In some embodiments, at least one R b It is a tertiary alkyl, silyl, or germanyl alkyl. In some embodiments, the tertiary alkyl is tert-butyl. In some embodiments, at least one pair of R a and R b Joining or fusion to form a ring.

[0417] In some embodiments, R b1 It is connected to C1 (carbon atom). In some such embodiments, R b1 It can be selected from the group consisting of the general substituents defined herein. In some such embodiments, R b1 The group consisting of preferred general substituents as defined herein can be selected. In some such embodiments, R b1 It is a tertiary alkyl, silyl, or germanyl group. In some such embodiments, R b1 It is a tertiary alkyl group. In some embodiments, the tertiary alkyl group is a tertiary butyl group. In some embodiments, R b2 It is connected to C2 (carbon atom). In some such embodiments, R b2 It can be selected from the group consisting of the general substituents defined herein. In some such embodiments, R b2 The group consisting of preferred general substituents as defined herein can be selected. In some such embodiments, R b2 It is a tertiary alkyl, silyl, or germanyl group. In some such embodiments, R b2 It is a tertiary alkyl group. In some embodiments, the tertiary alkyl group is a tertiary butyl group. In some embodiments, R b3 It is connected to C3 (carbon atom). In some such embodiments, R b3 It can be selected from the group consisting of the general substituents defined herein. In some such embodiments, R b3 The group consisting of preferred general substituents as defined herein can be selected. In some such embodiments, R b3 It is a tertiary alkyl, silyl, or germanyl group. In some such embodiments, R b3 It is a tertiary alkyl group. In some embodiments, the tertiary alkyl group is a tertiary butyl group. In some embodiments, R b4 It is bonded to C4 (carbon atom). In some such embodiments, R b4 It can be selected from the group consisting of the general substituents defined herein. In some such embodiments, R b4 The group consisting of preferred general substituents as defined herein can be selected. In some such embodiments, R b4 It is a tertiary alkyl, silyl, or germanyl group. In some such embodiments, R b4 It is a tertiary alkyl group. In some embodiments, the tertiary alkyl group is a tertiary butyl group.

[0418] In some embodiments, the compound has the formula Ir(L A 3. Formula Ir(L) A (L) Bk )2. Equation Ir(L A )2(L Bk ), formula Ir(L A )2(L Cj-I ) or formula Ir(L A )2(L Cj-II ),

[0419] Where L A As described in this article, including L A1 (V1)(V1)(V1)(V1)(O1) to L A11 (V192)(V192)(V192)(V192)(O328)、L A12 (V1)(V1)(V1)(V1)(O1) to L A37 (V192)(V192)(V192)(V180)(O328)、L A38 (V1)(V1)(V1)(V1)(O1) to L A43 (V192)(V192)(V192)(V178)(O328)、L A'1 (V1)(V1)(V1)(V1)(O1) to L A'12 (V192)(V192)(V192)(V192)(O328) and L A'13 (V1)(V1)(V1)(V1)(V1)(O1) to L A'26 (V192)(V192)(V192)(V192)(V178)(O328);

[0420] Where k is an integer from 1 to 543, and each L Bk It has the structure defined in Listing 6 below:

[0421]

[0422]

[0423]

[0424]

[0425]

[0426]

[0427]

[0428]

[0429]

[0430]

[0431]

[0432]

[0433]

[0434] Each L Cj-I With a based The structure; and

[0435] Each L Cj-II With a based The structure, where for L Cj-I and L Cj-II Each L in Cj R 201 and R 202 Each is defined independently as shown in Listing 7 below:

[0436]

[0437]

[0438]

[0439]

[0440]

[0441]

[0442]

[0443]

[0444]

[0445] Where R D1 To R D246 It has the structure shown in Listing C:

[0446]

[0447]

[0448]

[0449]

[0450]

[0451] In some embodiments, the compound is selected from only L Bk The group consisting of compounds that correspond to one of the following: L B1 L B30 L B31 L B109 L B110 L B112 L B113 L B114 L B125 L B127 L B138 L B140 L B149 L B150 L B170 L B171 L B172 L B174 L B208 L B241 L B312 L B315 L B356 L B357 L B367 L B371 L B382 L B439 L B440 L B455 L B456 L B457 L B458 L B461 L B462 L B463 L B469 and L B476 .

[0452] In some embodiments, the compound is selected from only L Bk The group consisting of compounds that correspond to one of the following: L B1 L B30 L B31 L B125 L B138 L B171 L B172 L B356 L B357 L B367 L B371 LB382 L B455 and L B456 .

[0453] In some embodiments, the compound is selected from only those having L Cj-I or L Cj-II The group of compounds that form the ligands, and the corresponding R of the ligands 201 and R 202 Defined as one of the following structures: R D1 R D3 R D4 R D5 R D9 R D10 R D17 R D18 R D20 R D22 R D37 R D40 R D41 R D42 R D43 R D48 R D49 R D50 R D54 R D55 R D58 R D59 R D78 R D79 R D81 R D87 R D88 R D89 R D93 R D116 R D117 R D118 R D119 R D120 R D133 R D134 R D135 R D136 R D143 R D144 R D145 R D146 R D147 R D149 R D151 R D154 R D155 R D161 R D175 R D190 R D193 R D200 R D201 R D206 R D210R D214 R D215 R D216 R D218 R D219 R D220 R D227 R D237 R D241 R D242 R D245 and R D246 .

[0454] In some embodiments, the compound is selected from only those having L Cj-I or L Cj-II The group of compounds that form the ligands, and the corresponding R of the ligands 201 and R 202 Defined as selected from one of the following structures: R D1 R D3 R D4 R D5 R D9 R D10 R D17 R D22 R D43 R D50 R D78 R D116 R D118 R D133 R D134 R D135 R D136 R D143 R D144 R D145 R D146 R D149 R D151 R D154 R D155 R D190 R D193 R D200 R D201 R D206 R D210 R D214 R D215 R D216 R D218 R D219 R D220 R D227 R D237 R D241 R D242 R D245 and R D246 .

[0455] In some embodiments, the compounds are selected only from those targeting L. Cj-I The group consisting of compounds whose ligands have one of the structures in the following list 8:

[0456]

[0457]

[0458] In some embodiments, the compound has a selection from Ir(L) A 3. Ir(L) A )2(L B ), Ir(L A (L) B )2、Ir(L A )2(L C ) and Ir(L A (L) B (L) C A group consisting of ) . In some embodiments, L A Select the group consisting of the structures of List 1, List 2, and List 3, L B Choose from lists 4, 5, and 6 (L) Bk A group consisting of structures, and L C Choose L as defined in Listing 7 Cj-I and L Cj-II A group composed of structures.

[0459] In some embodiments, L A Select the group consisting of the structures in list 1, and L B Choose freely L Bk A group consisting of structures. In some embodiments, L A Select the group consisting of the structures in list 2, and L B Choose freely L Bk A group consisting of structures. In some embodiments, L A Selected from List 3 as defined in this article, and L B Choose freely L Bk A group consisting of structures, where k is an integer from 1 to 543. In some embodiments, L A Selected from Listing 1 as defined in this article, and L C Choose freely L Cj-I and L Cj-II A group consisting of structures, where j is an integer from 1 to 1416.

[0460] In some embodiments, the compound may have Ir(L) A1 (V1)(V1)(V1)(V1)(O1))3 to Ir(LA11 The compound of formula Ir(L) is composed of (V192)(V192)(V192)(V192)(O328))3. Ai (R H (R) I (R) J (R) K (R) L ))3, by Ir(L A1 (V1)(V1)(V1)(V1)(O1))(L B1 )2 to Ir(L A11 (V192)(V192)(V192)(V192)(O328))(L B543 The compound of formula Ir(L)2 Ai (R H (R) I (R) J (R) K (R) L ))(L Bk 2. From Ir(L) A1 (V1)(V1)(V1)(V1)(O1))2(L B1 ) to Ir(L A11 (V192)(V192)(V192)(V192)(O328))2(L B543 The compound of formula Ir(L) Ai (R H (R) I (R) J (R) K (R) L ))2(L Bk ), by Ir(L A1 (V1)(V1)(V1)(V1)(O1))2(L C1-I ) to Ir(L A11 (V192)(V192)(V192)(V192)(O328))2(L C1416-I The compound of formula Ir(L) Ai (R H (R) I (R) J (R) K (R) L ))2(L Cj-I ), by Ir(L A1 (V1)(V1)(V1)(V1)(O1))2(L C1-II ) to Ir(L A11 (V192)(V192)(V192)(V192)(O328))2(LC1416-II The compound of formula Ir(L) Ai (R H (R) I (R) J (R) K (R) L ))2(L Cj-II ), by Ir(L A1 (V1)(V1)(V1)(V1)(O1))(L B1 (L) C1-I ) to Ir(L A11 (V192)(V192)(V192)(V192)(O328))(L B543 (L) C1416-I The compound of formula Ir(L) Ai (R H (R) I (R) J (R) K (R) L ))(L Bk (L) Cj-I ) or by Ir(L A1 (V1)(V1)(V1)(V1)(O1))(L B1 (L) C1-II ) to Ir(L A11 (V192)(V192)(V192)(V192)(O328))(L B543 (L) C1416-II The compound of formula Ir(L) Ai (R H (R) I (R) J (R) K (R) L ))(L Bk (L) Cj-II ), where L Ai (R H (R) I (R) J (R) K (R) L L Bk and L Cj-I and L Cj-II All of these are defined in this article.

[0461] In some embodiments, the compound may have Ir(L) A12 (V1)(V1)(V1)(V1)(O1))3 to Ir(L A37The Ir(L) compound composed of (V192)(V192)(V192)(V180)(O328))3 Ai' (R H (R) I (R) J (R) K' (R) L ))3, by Ir(L A12 (V1)(V1)(V1)(V1)(O1))(L B1 )2 to Ir(L A37 (V192)(V192)(V192)(V180)(O328))(L B543 The compound of formula Ir(L)2 Ai' (R H (R) I (R) J (R) K' (R) L ))(L Bk 2. From Ir(L) A12 (V1)(V1)(V1)(V1)(O1))2(L B1 ) to Ir(L A37 (V192)(V192)(V192)(V180)(O328))2(L B543 The compound of formula Ir(L) Ai' (R H (R) I (R) J (R) K' (R) L ))2(L Bk ), by Ir(L A12 (V1)(V1)(V1)(V1)(O1))2(L C1-I ) to Ir(L A37 (V192)(V192)(V192)(V180)(O328))2(L C1416-I The compound of formula Ir(L) Ai' (R H (R) I (R) J (R) K' (R) L ))2(L Cj-I ), by Ir(L A12 (V1)(V1)(V1)(V1)(O1))2(L C1-II ) to Ir(L A37 (V192)(V192)(V192)(V180)(O328))2(L C1416-IIThe compound of formula Ir(L) Ai' (R H (R) I (R) J (R) K' (R) L ))2(L Cj-II ), by Ir(L A12 (V1)(V1)(V1)(V1)(O1))(L B1 (L) C1-I ) to Ir(L A37 (V192)(V192)(V192)(V180)(O328))(L B543 (L) C1416-I The compound of formula Ir(L) Ai' (R H (R) I (R) J (R) K' (R) L ))(L Bk (L) Cj-I ) or by Ir(L A12 (V1)(V1)(V1)(V1)(O1))(L B1 (L) C1-II ) to Ir(L A37 (V192)(V192)(V192)(V180)(O328))(L B543 (L) C1416-II The compound of formula Ir(L) Ai' (R H (R) I (R) J (R) K' (R) L ))(L Bk (L) Cj-II ), where L Ai' (R H (R) I (R) J (R) K' (R) L L Bk and L Cj-I and L Cj-II All of these are defined in this article.

[0462] In some embodiments, the compound may have Ir(L) A38 (V1)(V1)(V1)(V1)(O1))3 to Ir(L A43 The compound of formula Ir(L) is composed of (V192)(V192)(V192)(V178)(O328))3.Ai” (R H (R) I (R) J (R) K” (R) L ))3, by Ir(L A38 (V1)(V1)(V1)(V1)(O1))(L B1 )2 to Ir(L A43 (V192)(V192)(V192)(V178)(O328))(L B543 The compound of formula Ir(L)2 Ai” (R H (R) I (R) J (R) K” (R) L ))(L Bk 2. From Ir(L) A38 (V1)(V1)(V1)(V1)(O1))2(L B1 ) to Ir(L A43 (V192)(V192)(V192)(V178)(O328))2(L B543 The compound of formula Ir(L) Ai” (R H (R) I (R) J (R) K” (R) L ))2(L Bk ), by Ir(L A38 (V1)(V1)(V1)(V1)(O1))2(L C1-I ) to Ir(L A43 (V192)(V192)(V192)(V178)(O328))2(L C1416-I The compound of formula Ir(L) Ai” (R H (R) I (R) J (R) K” (R) L ))2(L Cj-I ), by Ir(L A38 (V1)(V1)(V1)(V1)(O1))2(L C1-II ) to Ir(L A43 (V192)(V192)(V192)(V178)(O328))2(L C1416-II The compound of formula Ir(L) Ai” (R H (R)I (R) J (R) K” (R) L ))2(L Cj-II ), by Ir(L A38 (V1)(V1)(V1)(V1)(O1))(L B1 (L) C1-I ) to Ir(L A43 (V192)(V192)(V192)(V178)(O328))(L B543 (L) C1416-I The compound of formula Ir(L) Ai” (R H (R) I (R) J (R) K” (R) L ))(L Bk (L) Cj-I ) or by Ir(L A38 (V1)(V1)(V1)(V1)(O1))(L B1 (L) C1-II ) to Ir(L A43 (V192)(V192)(V192)(V178)(O328))(L B543 (L) C1416-II The compound of formula Ir(L) Ai” (R H (R) I (R) J (R) K” (R) L ))(L Bk (L) Cj-II ), where L Ai” (R H (R) I (R) J (R) K” (R) L L Bk and L Cj-I and L Cj-II All of these are defined in this article.

[0463] In some embodiments, the compound may have Ir(L) A'1 (V1)(V1)(V1)(V1)(O1))3 to Ir(L A'12 The compound of formula Ir(L) is composed of (V192)(V192)(V192)(V192)(O328))3. A'n (R H (R) I(R) J (R) K (R) L ))3, by Ir(L A'1 (V1)(V1)(V1)(V1)(O1))(L B1 )2 to Ir(L A'12 (V192)(V192)(V192)(V192)(O328))(L B543 The compound of formula Ir(L)2 A'n (R H (R) I (R) J (R) K (R) L ))(L Bk 2. From Ir(L) A'1 (V1)(V1)(V1)(V1)(O1))2(L B1 ) to Ir(L A'12 (V192)(V192)(V192)(V192)(O328))2(L B543 The compound of formula Ir(L) A'n (R H (R) I (R) J (R) K (R) L ))2(L Bk ), by Ir(L A'1 (V1)(V1)(V1)(V1)(O1))2(L C1-I ) to Ir(L A'12 (V192)(V192)(V192)(V192)(O328))2(L C1416-I The compound of formula Ir(L) A'n (R H (R) I (R) J (R) K (R) L ))2(L Cj-I ), by Ir(L A'1 (V1)(V1)(V1)(V1)(O1))2(L C1-II ) to Ir(L A'12 (V192)(V192)(V192)(V192)(O328))2(L C1416-II The compound of formula Ir(L) A'n (R H (R) I (R) J (R) K(R) L ))2(L Cj-II ), by Ir(L A'1 (V1)(V1)(V1)(V1)(O1))(L B1 (L) C1-I ) to Ir(L A'12 (V192)(V192)(V192)(V192)(O328))(L B543 (L) C1416-I The compound of formula Ir(L) A'n (R H (R) I (R) J (R) K (R) L ))(L Bk (L) Cj-I ) or by Ir(L A'1 (V1)(V1)(V1)(V1)(O1))(L B1 (L) C1-II ) to Ir(L A'12 (V192)(V192)(V192)(V192)(O328))(L B543 (L) C1416-II The compound of formula Ir(L) A'n (R H (R) I (R) J (R) K (R) L ))(L Bk (L) Cj-II ), where L A'n (R H (R) I (R) J (R) K (R) L L Bk and L Cj-I and L Cj-II All of these are defined in this article.

[0464] In some embodiments, the compound may have Ir(L) A'13 (V1)(V1)(V1)(V1)(V1)(O1))3 to Ir(L A'26 The compound of formula Ir(L) is composed of (V192)(V192)(V192)(V178)(O328))3. A'n' (R H (R) I (R) J (R) K (R)K” (R) L ))3, by Ir(L A'13 (V1)(V1)(V1)(V1)(V1)(O1))(L B1 )2 to Ir(L A'26 (V192)(V192)(V192)(V192)(V178)(O328))(L B543 The compound of formula Ir(L)2 A'n' (R H (R) I (R) J (R) K (R) K” (R) L ))(L Bk 2. From Ir(L) A'13 (V1)(V1)(V1)(V1)(V1)(O1))2(L B1 ) to Ir(L A'26 (V192)(V192)(V192)(V192)(V178)(O328))2(L B543 The compound of formula Ir(L) A'n' (R H (R) I (R) J (R) K (R) K” (R) L ))2(L Bk ), by Ir(L A'13 (V1)(V1)(V1)(V1)(V1)(O1))2(L C1-I ) to Ir(L A'26 (V192)(V192)(V192)(V192)(V178)(O328))2(L C1416-I The compound of formula Ir(L) A'n' (R H (R) I (R) J (R) K (R) K” (R) L ))2(L Cj-I ), by Ir(L A'13 (V1)(V1)(V1)(V1)(V1)(O1))2(L C1-II ) to Ir(L A'26 (V192)(V192)(V192)(V192)(V178)(O328))2(L C1416-II The compound of formula Ir(L)A'n' (R H (R) I (R) J (R) K (R) K” (R) L ))2(L Cj-II ), by Ir(L A'13 (V1)(V1)(V1)(V1)(V1)(O1))(L B1 (L) C1-I ) to Ir(L A'26 (V192)(V192)(V192)(V192)(V178)(O328))(L B543 (L) C1416-I The compound of formula Ir(L) A'n' (R H (R) I (R) J (R) K (R) K” (R) L ))(L Bk (L) Cj-I ) or by Ir L A'13 (V1)(V1)(V1)(V1)(V1)(O1))(L B1 (L) C1-II ) to Ir(L A'26 (V192)(V192)(V192)(V192)(V178)(O328))(L B543 (L) C1416-II The compound of formula Ir(L) A'n' (R H (R) I (R) J (R) K (R) K” (R) L ))(L Bk (L) Cj-II ), where L A'n' (R H (R) I (R) J (R) K (R) K” (R) L L Bk and L Cj-I and L Cj-II All of these are defined in this article.

[0465] In some embodiments, the compound is selected from the group consisting of the structures listed in List 9 below:

[0466]

[0467]

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477] In some embodiments, the compound may be

[0478]

[0479] In some embodiments, a first ligand L having a structure comprising Formula I as described herein A The compounds are partially or fully deuterated. In some embodiments, the compounds are fully deuterated. In some embodiments, the compounds of formula I described herein have a first ligand L. A The compound may be at least 30% deuterated, at least 40% deuterated, at least 50% deuterated, at least 60% deuterated, at least 70% deuterated, at least 80% deuterated, at least 90% deuterated, at least 95% deuterated, at least 99% deuterated, or 100% deuterated. As used herein, the percentage of deuteration has its general meaning and includes the percentage of all possible hydrogen atoms (e.g., hydrogen or deuterium positions) occupied by deuterium atoms in the compound. In some embodiments, the carbon atoms constituting the ring coordinated to the metal M are fully or partially deuterated. In some embodiments, the carbon atoms contained in the polycyclic system coordinated to the metal M are fully or partially deuterated. In some embodiments, the substituents connected to the monocyclic or fused polycyclic system coordinated to the metal M are fully or partially deuterated.

[0480] In some embodiments, the Formula I compound emits at room temperature with a full width at half maximum (FWHM) equal to or less than 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5 nm. A narrower FWHM means better color purity for OLED display applications.

[0481] As defined above, M(L) A ) p (L B ) q (L C ) r In some embodiments of the heteroligand compound, ligand L A Having the first substituent R I The first substituent R I The first atom aI in ligand L A Of all the atoms, the one furthest from the metal M is ligand L. B (If present) has a second substituent R II The second substituent R II The first atom α-II in ligand L B Of all the atoms, ligand L is the furthest from metal M. Furthermore, ligand L... C (If present) Having a third substituent R III The third substituent R III The first atom α-III in ligand L C Of all the atoms, it is the farthest from the metal M.

[0482] In such heterocomplexes, the vector V can be defined as follows: D1 V D2 and V D3 V D1 Let V represent the direction from metal M to the first atom aI, and let V be the vector. D1 The value of D 1 This indicates that metal M and the first substituent R I The straight-line distance between the first atoms aI in V. D2 This represents the direction from metal M to the first atom a-II, and the vector V D2 The value of D 2 This indicates that metal M and the second substituent R II The straight-line distance between the first atom a-II in V. D3 This represents the direction from metal M to the first atom a-III, and the vector V D3 The value of D 3 This indicates that metal M and the third substituent R III The straight-line distance between the first atom a-III in the matrix.

[0483] In such heterocomplexes, a sphere with radius r is defined, the center of which is a metal M, and the radius r is such that the sphere encloses a non-substituent R in the compound. I R II and R III The minimum radius of all atoms in a portion; and where D 1 D 2 and D 3 At least one of them is at least larger than the radius r In some embodiments, D 1 D 2 and D 3 At least one of them is at least 2.9, 3.0, 4.3, 4.4, 5.2, 5.9, 7.3, 8.8, 10.3, 13.1, 17.6 or larger than the radius r. In some embodiments, D 1 D 2 and D 3 At least two of them are at least 1.5, 2.9, 3.0, 4.3, 4.4, 5.2, 5.9, 7.3, 8.8, 10.3, 13.1, 17.6 or larger than the radius r.

[0484] In some embodiments of such heteropolymer compounds, the compound has a transition dipole moment axis, and the transition dipole moment axis is related to the vector V. D1 V D2 and V D3 The angle between them is defined, where the transition dipole moment axis and the vector V are... D1 V D2 and V D3 At least one angle between them is less than 40°. In some embodiments, the transition dipole moment axis and the vector V are... D1 V D2 and V D3 At least one angle between them is less than 30°, 20°, 15°, or 10°. In some embodiments, the transition dipole moment axis is related to the vector V. D1 V D2 and V D3 At least two angles between them are less than 20°. In some embodiments, the transition dipole moment axis and the vector V... D1 V D2 and V D3 At least two of the angles between them are less than 15° or 10°.

[0485] In some embodiments, the transition dipole moment axis and vector V D1 V D2 and V D3 All three angles between them are less than 20°. In some embodiments, the transition dipole moment axis is related to the vector V. D1V D2 and V D3 All three angles between them are less than 15° or 10°.

[0486] In some embodiments of such heteropolymer compounds, the compound has a vertical dipole ratio (VDR) of 0.33 or less. In some embodiments of such heteropolymer compounds, the compound has a VDR of 0.30, 0.25, 0.20, or 0.15 or less.

[0487] Those skilled in the art will readily understand the meaning of the terms "transition dipole moment axis" and "vertical dipole ratio" of a compound. However, the meanings of these terms can be found in U.S. Patent No. 10,672,997, the disclosure of which is incorporated herein by reference in its entirety. In U.S. Patent No. 10,672,997, the horizontal dipole ratio (HDR) of the compound is discussed, not the VDR. However, those skilled in the art will readily understand that VDR = 1 - HDR.

[0488] In some embodiments, the compound may be an emission dopant. In some embodiments, the compound may generate emission via phosphorescence, fluorescence, thermally activated delayed fluorescence, triplet-triplet annihilation, or a combination of these methods. In some embodiments, the emission dopant may be a racemic mixture or may be enriched with one enantiomer. In some embodiments, the compounds of the present invention may have different stereoisomers, such as fac and mer. The present compounds relate to individual isomers and mixtures of various isomers in any mixing ratio. In some embodiments, the compound may be homogeneous (each ligand is the same). In some embodiments, the compound may be mixed (at least one ligand is different from the others). In some embodiments, when more than one ligand coordinated to a metal is present, the ligands may all be the same. In some other embodiments, at least one ligand is different from the other ligands. In some embodiments, each ligand may be different from all the other ligands. This also holds true in embodiments where a ligand coordinated to a metal may be linked to other ligands coordinated to the metal to form a tridentate, tetradentate, pentadentate, or hexadentate ligand. Therefore, in the case where the ligands are linked together, in some embodiments all the ligands may be the same, and in some other embodiments at least one of the linked ligands may be different from the other ligands.

[0489] In another aspect of this disclosure, a formulation comprising the novel compounds disclosed herein is described. The formulation may include one or more components selected from the group consisting of: solvent, emitter, host, hole injection material, hole transport material, electron blocking material, hole blocking material, and electron transport material.

[0490] This disclosure covers the chemical structure of any novel compound comprising this disclosure or its monovalent or multivalent variants. In other words, the compound of the present invention or its monovalent or multivalent variants may be part of a larger chemical structure. Such chemical structures may be selected from the group consisting of monomers, polymers, macromolecules, and supramolecular (also called supermolecules). As used herein, a “monovalent variant of a compound” refers to the same part of the compound, but in which one hydrogen has been removed and replaced with a bond to the rest of the chemical structure. As used herein, a “multivalent variant of a compound” refers to the same part of the compound, but in which more than one hydrogen has been removed and replaced with one or more bonds to the rest of the chemical structure. In the case of supramolecular compounds, the compound of the present invention may also be incorporated into supramolecular complexes without covalent bonds. As used in this context, the description of structure A comprising part B means that structure A comprises the structure of part B, the structure of which does not include H or D atoms that can be attached to part B. This is because at least one H or D on a given part of the structure must be replaced with a substituent so that part B may be part of structure A, and after it becomes part of structure A, one or more of the H or D on the given part of the structure B may be further substituted.

[0491] C. OLEDs and devices disclosed herein

[0492] In another aspect, this disclosure also provides an OLED device comprising a first organic layer containing compounds as disclosed in the above compound portion of this disclosure.

[0493] In some embodiments, an OLED includes: an anode; a cathode; and an organic layer disposed between the anode and the cathode, wherein the organic layer includes a first ligand L. A Compounds comprising the structure of Formula I as described herein.

[0494] In some embodiments, the organic layer is selected from the group consisting of HIL, HTL, EBL, EML, HBL, ETL, and EIL. In some embodiments, the organic layer may be an emission layer and the compound as described herein may be an emission dopant or a non-emission dopant.

[0495] In some embodiments, the organic layer may further comprise a body, wherein the body comprises at least one chemical group selected from the group consisting of: triphenylene, carbazole, indolocarbazole, dibenzothiophene, dibenzofuran, dibenzoselenene, 5λ 2-Benzo[d]benzo[4,5]imidazo[3,2-a]imidazolium, 5,9-dioxa-13b-boronazona[3,2,1-de]anthracene, azacyclohexylborane, oxaborane, dihydroacridine, oxanthracene, dihydrobenzoazasilane, dibenzooxasiline, phenoxazine, phenoxthiazine, dihydrophenazine, fluorene, naphthalene, anthracene, phenanthrene, phenanthroline, benzoquinoline, quinoline, isoquinoline, quinazoline, pyrimidine, pyrazine, pyridine, triazine, borylalkyl, silylalkyl, aza-triphenylene, aza-carbazole, aza-indolocarbazole, aza-dibenzothiophene, aza-dibenzofuran, aza-dibenzoselenophene, aza-5λ 2 - benzo[d]benzo[4,5]imidazo[3,2-a]imidazo and aza-(5,9-dioxa-13b-boronanaphtho[3,2,1-de]anthracene).

[0496] In some embodiments, the subject may be selected from the group of structures in the following subject group 1:

[0497]

[0498]

[0499]

[0500]

[0501]

[0502]

[0503] in:

[0504] Each of J1 to J6 is independently C or N; L' is a direct bond or an organic linking group;

[0505] Each Y AA Y BB Y CC and Y DD Independently select from the following groups: non-existent bond, direct bond, O, S, Se, CRR', SiRR', GeRR', NR, BR, BRR';

[0506] R A' R B' R C' R D' R E' R F' and R G'Each of these terms independently represents monosubstituted, at most maximum substituted, or unsubstituted.

[0507] Each R, R', R A' R B' R C' R D' R E' R F' and R G' Substituents are independently hydrogen or selected from the group of general substituents as defined herein; any two substituents may join or fuse to form a ring;

[0508] Furthermore, where possible, each unsubstituted aromatic carbon atom can be replaced by one or more N atoms to form a nitrogen-substituted ring.

[0509] In some embodiments, L' is an organic linking group selected from the group consisting of: BR, BRR', NR, PR, P(O)R, O, S, Se, C=O, C=S, C=Se, C=NR, C=CRR', S=O, SO2, CR, CRR', SiRR', GeRR', alkylene, cycloalkyl, aryl, cycloalkylene, arylene, heteroarylene, and combinations thereof.

[0510] In some embodiments, at least one of J1 to J3 is N. In some embodiments, at least two of J1 to J3 are N. In some embodiments, all three of J1 to J3 are N. In some embodiments, each Y CC and Y DD Independently, it is O, S, or SiRR', or more preferably O or S. In some embodiments, at least one unsubstituted aromatic carbon atom is substituted with N to form a nitrogen heterocycle.

[0511] In some embodiments, the subject is selected from the group consisting of: EG1-MG1-EG1 to EG53-MG27-EG53 having the formula EGa-MGb-EGc, or EG1-EG1 to EG53-EG53 having the formula EGa-EGc when MGb is absent, where a is an integer from 1 to 53, b is an integer from 1 to 27, and c is an integer from 1 to 53. The structures of EG1 to EG53 are shown below:

[0512]

[0513]

[0514]

[0515] The structural diagrams of MG1 through MG27 are shown below:

[0516]

[0517] In the MGb structure shown above, the two bond positions in the asymmetric structures MG10, MG11, MG12, MG13, MG14, MG17, MG24 and MG25 are marked with numbers for identification purposes.

[0518] In some embodiments, the subject can be any of its nitrogen-substituted variants, its fully or partially deuterated variants, and combinations thereof. In some embodiments, the subject has the formula EGa-MGb-Egc and is selected from the group consisting of h1 to h112 as defined in the following list of subjects group 2, wherein each of MGb, EGa, and EGc is defined as follows:

[0519]

[0520]

[0521] In the table above, the EGa and EGc structures bonded to one of the asymmetric structures MG10, MG11, MG12, MG13, MG14, MG17, MG24 and MG25 are marked with a numerical prefix, which indicates their bond position in the MGb structure.

[0522] In some embodiments, the organic layer may further comprise a body, wherein the body comprises a metal complex.

[0523] In some embodiments, the emitter layer may comprise two bodies: a first body and a second body. In some embodiments, the first body is a hole transport body and the second body is an electron transport body. In some embodiments, the first body is a hole transport body and the second body is a bipolar body. In some embodiments, the first body is an electron transport body and the second body is a bipolar body. In some embodiments, the first body and the second body may form an excited-state complex. In some embodiments, the emitter layer may comprise a third body. In some embodiments, the third body is selected from the group consisting of: an insulating body (wide bandgap body), a hole transport body, and an electron transport body. In some embodiments, the third body forms an excited-state complex with one of the first body and the second body, or with both of the first body and the second body. In some embodiments, the emitter layer may comprise a fourth body. In some embodiments, the fourth body is selected from the group consisting of: an insulating body (wide bandgap body), a hole transport body, and an electron transport body. In some embodiments, the fourth body forms an excited-state complex with one of the first body, the second body, and the third body, with two of the first body, the second body, and the third body, or with each of the first body, the second body, and the third body. In some embodiments, the LUMO of the electron transport host is less than -2.4 eV, less than -2.5 eV, less than -2.6 eV, or less than -2.7 eV. In some embodiments, the HOMO of the hole transport host is greater than -5.6 eV, greater than -5.5 eV, greater than -5.4 eV, or greater than -5.35 eV. HOMO and LUMO values ​​can be determined using solution electrochemistry. Solution cyclic voltammetry and differential pulse voltammetry can be performed using a CH instrument model 6201B potentiostat, using anhydrous dimethylformamide (DMF) solvent and tetrabutylammonium hexafluorophosphate as the supporting electrolyte. Glassy carbon, platinum wire, and silver wire are used as the working electrode, counter electrode, and reference electrode, respectively. The electrochemical potential can be referenced to the internal ferrocene-ferrocene redox pair (Fc / Fc+) by measuring the peak potential difference using differential pulse voltammetry. The corresponding highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energies were determined by referring to the literature on the cationic and anionic redox potentials of ferrocene (4.8 eV compared to vacuum) ((a) Fink, R.; Heischkel, Y.; Thelakkat, M.; Schmidt, H.-W., Chem. Mater., 1998, 10, 3620-3625).(b) Pommerehne, J.; Vestweber, H.; Guss, W.; Mahrt, RF.; Bassler, H.; Porsch, M.; Daub, J. Adv. Mater. 1995, 7, 551.

[0524] In some embodiments, the compound described herein may be a sensitizer or a component of a sensitizer; wherein the device may further include a receptor that receives energy from the sensitizer. In some embodiments, the receptor is an emitter in the device. In some embodiments, the receptor may be a fluorescent material. In some embodiments, the compound described herein may be used as a phosphorescent sensitizer in an OLED, wherein one or more layers in the OLED contain receptors in the form of one or more non-delayed fluorescence and / or delayed fluorescence materials. In some embodiments, the compound described herein may be used as a component of an excited-state complex used as a sensitizer. As a phosphorescent sensitizer, the compound must be able to transfer energy to the receptor and the receptor to emit energy or further transfer energy to the final emitter. The receptor concentration may range from 0.001% to 99.9%. The receptor may be in the same layer as the phosphorescent sensitizer or in one or more different layers. In some embodiments, the receptor is a thermally activated delayed fluorescence (TADF) material. In some embodiments, the receptor is a non-delayed fluorescence material. In some embodiments, emission may be generated by any one or all of the sensitizer, the receptor, and the final emitter. In some embodiments, the receptor emits at room temperature with a full width at half maximum (FWHM) equal to or less than 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5 nm. A narrower FWHM indicates better color purity for OLED display applications.

[0525] As used herein, phosphorescence generally refers to photon emission when the electron spin quantum number changes, i.e., the initial and final states of emission have different electron spin quantum numbers, such as from T1 to S0. Most Ir and Pt complexes currently used in OLEDs are phosphorescent emitters. In some embodiments, such excited-state complexes can also emit phosphorescence if the formation involves a triplet emitter. On the other hand, fluorescent emitters generally refer to photon emission when the electron spin quantum number remains constant, such as from S1 to S0 or from D1 to D0. Fluorescent emitters can be delayed or non-delayed fluorescent emitters. Depending on the spin state, fluorescent emitters can be singlet, doublet, or other multiplyt emitters. It is believed that the internal quantum efficiency (IQE) of fluorescent OLEDs can exceed the 25% spin statistical limit through delayed fluorescence. Two types of delayed fluorescence exist: P-type and E-type delayed fluorescence. P-type delayed fluorescence is generated by triplet-triplet annihilation (TTA). On the other hand, E-type delayed fluorescence does not depend on the collision of two triplet states, but rather on the thermal population between the triplet and singlet excited states. Thermal energy can activate the triplet state to transition back to the singlet state. This type of delayed fluorescence is also known as TADF. E-type delayed fluorescence characteristics can be seen in excited-state complex systems or single compounds. Without being bound by theory, it is assumed that TADF emission requires a small singlet-triplet bandgap (ΔE) less than or equal to 400, 350, 300, 250, 200, 150, 100, or 50 meV. S-T These are compounds or excited-state complexes of electron transport compounds (TADFs). There are two main types of TADF emitters: one called donor-acceptor TADF and the other called multi-resonant (MR) TADF. Typically, single-compound donor-acceptor TADF compounds are constructed by connecting an electron donor moiety (such as an amino or carbazole derivative) and an electron acceptor moiety (such as an N-containing six-membered aromatic ring or a cyano-substituted aromatic ring). Donor-acceptor excited-state complexes can be formed between hole-transporting compounds and electron-transporting compounds. Examples of MR-TADF materials include highly conjugated fused-ring systems. In some embodiments, MR-TADF materials contain boron, carbon, and nitrogen atoms. Such materials may also contain other atoms, such as oxygen. In some embodiments, the reverse intersystem crossing time from T1 to S1 for delayed fluorescence emission at 293 K is less than or equal to 10 microseconds. In some embodiments, such a time can be greater than 10 microseconds and less than 100 microseconds.

[0526] In some embodiments, the OLED may include additional compounds selected from the group consisting of: non-delayed fluorescent materials, delayed fluorescent materials, phosphorescent materials, and combinations thereof.

[0527] In some embodiments, the compounds of the present invention described herein are phosphorescent materials.

[0528] In some embodiments, the phosphorescent material is an emitter that emits light within the OLED. In some embodiments, the phosphorescent material does not emit light within the OLED. In some embodiments, the phosphorescent material transfers its excited state to another material within the OLED. In some embodiments, the phosphorescent material participates in charge transport within the OLED. In some embodiments, the phosphorescent material is a sensitizer or a component of a sensitizer, and the OLED further includes an acceptor. In some embodiments, the phosphorescent material forms an excited-state complex with another material within the OLED (e.g., a host material, an emitter material).

[0529] In some embodiments, the non-delayed fluorescent material or the delayed fluorescent material is an emitter that emits light within the OLED. In some embodiments, the non-delayed fluorescent material or the delayed fluorescent material does not emit light within the OLED. In some embodiments, the non-delayed fluorescent material or the delayed fluorescent material transfers its excited state to another material within the OLED. In some embodiments, the non-delayed fluorescent material or the delayed fluorescent material participates in charge transport within the OLED. In some embodiments, the non-delayed fluorescent material or the delayed fluorescent material is an acceptor, and the OLED further includes a sensitizer.

[0530] In some embodiments of OLEDs, the delayed fluorescence material comprises at least one donor group and at least one acceptor group. In some embodiments, the delayed fluorescence material is a metal complex. In some embodiments, the delayed fluorescence material is a non-metallic complex. In some embodiments, the delayed fluorescence material is a Pt, Pd, Zn, Cu, Ag, or Au complex (some of which are also referred to as metal-assisted (MA)TADF). In some embodiments, the metal-assisted delayed fluorescence material comprises a metal-carbamate bond. In some embodiments, the non-delayed fluorescence material or the delayed fluorescence material comprises at least one chemical group selected from the group consisting of: arylamine, aryloxy, arylthio, triphenylene, carbazole, indolocarbazole, dibenzothiophene, dibenzofuran, dibenzoselenene, 5λ 2 -Benzo[d]benzo[4,5]imidazo[3,2-a]imidazo, 5,9-dioxa-13b-boronazona[3,2,1-de]anthracene, 5λ 2 ,9λ 2 -diaza-13b-boronanaphene[2,3,4-de]anthracene, 5-oxa-9λ 2-aza-13b-boronazonaphtho[3,2,1-de]anthracene, azacyclohexylborane, oxaborane, dihydroacridine, oxanthracene, dihydrobenzoazasilane, dibenzooxasilane, phenoxazine, phenoxthiazine, dihydrophenoxazine, fluorene, naphthalene, anthracene, phenanthrene, phenanthroline, benzoquinoline, quinoline, isoquinoline, quinazoline, pyrimidine, pyrazine, pyridine, triazine, borane, amino, silane, their aza variants and combinations thereof. In some embodiments, the non-delayed fluorescent material or the delayed fluorescent material comprises tri(aryl / heteroaryl)borane, wherein one or more pairs of substituents from the aryl / heteroaryl group are bonded to form a ring. In some embodiments, the fluorescent material comprises at least one chemical group selected from the group consisting of: naphthalene, anthracene, phenanthrene, fluorene, pyrene, Perylene and azurite.

[0531] In another aspect, the OLED of this disclosure may further include an emission region containing a compound or formulation of a compound as disclosed in the foregoing compound portion of this disclosure. In some embodiments, the emission region may include: having a first ligand L A The compound or a formulation thereof, the compound comprising a structure of Formula I as described herein. In some embodiments, the emission region comprises one or more organic layers, wherein at least one of the one or more organic layers has a minimum thickness selected from the group consisting of: 350, 400, 450, 500, 550, 600, 650 and In some embodiments, at least one of the one or more organic layers is formed by an emission system having a figure of merit (FOM) equal to or greater than a value selected from the group consisting of: 2.50, 2.55, 2.60, 2.65, 2.70, 2.75, 2.80, 2.85, 2.90, 2.95, 3.00, 5.00, 10.0, 15.0, and 20.0. A definition of FOM is available in U.S. Patent Application Publication No. 2023 / 0292605, the entire contents of which are incorporated herein by reference. In some embodiments, at least one of the one or more organic layers comprises a compound or formulation of a compound as disclosed in Parts A and D of this disclosure.

[0532] In some embodiments, the OLED or emitting region comprising the compound of the present invention disclosed herein may be incorporated into a full-color pixel arrangement of a device. Such a full-color pixel arrangement of a device comprises at least one pixel, wherein the at least one pixel comprises a first sub-pixel and a second sub-pixel. The first sub-pixel comprises a first OLED, which comprises a first emitting region. The second sub-pixel comprises a second OLED, which comprises a second emitting region. In some embodiments, the first and / or second OLEDs, the first and / or second emitting regions may be the same or different and may each independently have various device features and embodiments comprising the compound of the present invention, as well as various combinations and sub-combinations of various device features and embodiments comprising the compound of the present invention, as disclosed herein.

[0533] In some embodiments, the first emission region is configured to emit light with a peak wavelength λ. max1 The second emission region is configured to emit light with a peak wavelength λ. max2 The light. In some embodiments, the peak wavelength λ max1 With λ max2 The difference between them is at least 4 nm but within the same color. For example, light blue and dark blue light as described above. In some embodiments, the first emission region is configured to emit light with a peak wavelength λ in one region of the visible spectrum at 400-500 nm, 500-600 nm, or 600-700 nm. max1 The light emitted; and the second emission region is configured to emit light having a peak wavelength λ in one of the remaining regions of the visible spectrum of 400-500 nm, 500-600 nm, and 600-700 nm. max2 The light emitted. In some embodiments, the first emitting region includes (if more than one) a first number of emitting layers deposited on top of another; and the second emitting region includes (if more than one) a second number of emitting layers deposited on top of another; and the first number is different from the second number. In some embodiments, both the first emitting region and the second emitting region contain phosphorescent materials that may be the same or different. In some embodiments, the first emitting region contains phosphorescent material, while the second emitting region contains fluorescent material. In some embodiments, both the first emitting region and the second emitting region contain fluorescent materials that may be the same or different.

[0534] In some embodiments, at least one pixel of an OLED or emitting region comprises a total of N sub-pixels; wherein the N sub-pixels include a first sub-pixel and a second sub-pixel; wherein each of the N sub-pixels includes an emitting region; wherein the total number of emitting regions within at least one pixel is equal to or less than N-1. In some embodiments, the second emitting region is identical to the first emitting region; and each sub-pixel of at least one pixel includes an emitting region identical to the first emitting region. In some embodiments, a full-color pixel arrangement may have multiple pixels including a first pixel region and a second pixel region; wherein at least one display feature in the first pixel region differs from a corresponding display feature in the second pixel region, and wherein the at least one display feature is selected from the group consisting of: resolution, cavity mode, color, external coupling, and color filter.

[0535] In some embodiments, the OLED is a stacked OLED comprising one or more charge generating layers (CGLs). In some embodiments, the OLED comprises a first electrode, a first emitting region disposed above the first electrode, a first CGL disposed above the first emitting region, a second emitting region disposed above the first CGL, and a second electrode disposed above the second emitting region. In some embodiments, the first emitting region and / or the second emitting region may have various device features as described above for pixelation devices. In some embodiments, the stacked OLED is configured to emit white. In some embodiments, one or more of the emitting regions in the pixelated OLED or stacked OLED comprise sensitizers and acceptors having various sensitization device features and various embodiments of the compounds of the present invention disclosed herein. For example, the first emitting region is included in a sensitization device while the second emitting region is not included in a sensitization device; in some cases, both the first and second emitting regions are included in a sensitization device.

[0536] In some embodiments, the OLED may emit at least 1%, 5%, 10%, 30%, 50%, 70%, 80%, 90%, 95%, 99%, or 100% of light from plasmonic modes. In some embodiments, at least one of the anode, cathode, or a new layer disposed above the organic emitting layer serves as a reinforcement layer. The reinforcement layer comprises a plasmonic material exhibiting surface plasmon resonance, which is nonradiatively coupled to the emitting material and transfers excited-state energy from the emitting material to the nonradiative modes of surface plasmon polaritons. In some embodiments, the reinforcement layer is positioned at a distance from the organic emitting layer not exceeding a threshold distance, wherein the emitting material has a total nonradiative decay rate constant and a total radiative decay rate constant due to the presence of the reinforcement layer. The threshold distance is the position where the total nonradiative decay rate constant equals the total radiative decay rate constant. Another threshold distance is the distance at which the total radiative decay rate constant divided by the sum of the total nonradiative decay rate constant and the total radiative decay rate constant equals the photoluminescence yield of the emitting material without the reinforcement layer.

[0537] In some embodiments, the OLED further includes an external coupling layer. In some embodiments, the external coupling layer is disposed above the enhancement layer on the side opposite the organic emitting layer. The external coupling layer scatters energy from surface plasmon polaritons. In some embodiments, this energy is scattered as photons into free space. In other embodiments, energy is scattered from the surface plasmon polariton modes of the device into other modes, such as, but not limited to, organic waveguide modes, substrate modes, or another waveguide mode. In some embodiments, one or more intermediary layers may be disposed between the enhancement layer and the external coupling layer. Examples of intermediary layers may be dielectric materials, including organic, inorganic, perovskite, and oxide materials, and may comprise stacks and / or mixtures of these materials.

[0538] The enhancement layer alters the effective properties of the medium in which the emitter material resides, thereby causing any or all of the following: reduced emissivity, altered emission profile, changes in emission intensity with angle, altered emitter material stability, altered OLED efficiency, and reduced roll-off efficiency of the OLED device. Placing the enhancement layer on the cathode side, anode side, or both sides, or placing the enhancement layer itself as a CGL, produces an OLED device that utilizes any of the aforementioned effects. In addition to the specific functional layers mentioned herein and illustrated in the various OLED examples shown in the figures, the OLED according to this disclosure may also include any other functional layers commonly found in OLEDs.

[0539] In some embodiments, the reinforcing layer may comprise a plasmonic material, an optically active metamaterial, or a hyperbolic metamaterial. In some embodiments, the plasmonic material comprises at least one metal. In such embodiments, the metal may comprise at least one of the following: Ag, Al, Au, Ir, Pt, Ni, Cu, W, Ta, Fe, Cr, Mg, Ga, Rh, Ti, Ru, Pd, In, Bi, or Ca, alloys or mixtures of these materials, and stacks of these materials. In some embodiments, the reinforcing layer is configured as a planar layer. In other embodiments, the reinforcing layer is characterized by wavelengths arranged periodically, quasi-periodically, or randomly, or by subwavelengths arranged periodically, quasi-periodically, or randomly.

[0540] In some embodiments, the outer coupling layer has a wavelength or subwavelength characteristic of being arranged periodically, quasi-periodically, or randomly. In some embodiments, the outer coupling layer may be composed of a plurality of nanoparticles. In some embodiments, the outer coupling layer is composed of a plurality of nanoparticles disposed on a material. In these embodiments, the outer coupling layer can be adjusted by at least one of the following: changing the size of the plurality of nanoparticles, changing the shape of the plurality of nanoparticles, changing the material of the plurality of nanoparticles, adjusting the thickness of the material, changing the refractive index of the material, adding an additional layer disposed on the plurality of nanoparticles, changing the thickness of a reinforcing layer, or changing the material of a reinforcing layer. The plurality of nanoparticles of the device may be formed from at least one of the following: metal, dielectric material, semiconductor material, metal alloy, mixture of dielectric materials, stack or layering of one or more materials and / or a core of one type of material coated with a shell of another type of material. In some embodiments, the outer coupling layer is composed of at least metal nanoparticles, wherein the metal is selected from the group consisting of: Ag, Al, Au, Ir, Pt, Ni, Cu, W, Ta, Fe, Cr, Mg, Ga, Rh, Ti, Ru, Pd, In, Bi, and Ca, alloys or mixtures of these materials, and stacks of these materials. In some embodiments, the outer coupling layer is formed by photolithography.

[0541] In some embodiments of the plasmonic device, the emitter and / or host compound used in the emitter layer has a vertical dipole ratio (VDR) of 0.33 or greater. In some such embodiments, the emitter and / or host compound has a VDR of 0.40, 0.50, 0.60, 0.70 or greater.

[0542] In another aspect, this disclosure also provides a consumer product comprising an organic light-emitting device (OLED) having an anode; a cathode; and an organic layer disposed between the anode and the cathode, wherein the organic layer may comprise compounds or formulations of compounds as disclosed in the above compound section of this disclosure.

[0543] In some embodiments, the consumer product includes an OLED having an anode, a cathode, and an organic layer disposed between the anode and the cathode, wherein the organic layer may include a first ligand L. A Compounds comprising the structure of Formula I as described herein.

[0544] Generally, an OLED comprises at least one organic layer disposed between and electrically connected to both the anode and cathode. When a current is applied, holes are injected into the anode and electrons into the organic layer from the cathode. The injected holes and electrons migrate toward their respective oppositely charged electrodes. When electrons and holes are localized on the same molecule, an "exciton" is formed, which is a localized electron-hole pair with an excited energy state. When the exciton relaxes through a photoemission mechanism, light is emitted. In some cases, excitons can be localized as excimers or excited-state complexes. Non-radiative mechanisms (such as thermal relaxation) may also occur, but are generally considered undesirable.

[0545] Figure 1 An organic light-emitting device 100 is shown. The figures are not necessarily drawn to scale. Device 100 may include a substrate 110, an anode 115, a hole injection layer (HIL) 120, a hole transport layer (HTL) 125, an electron blocking layer (EBL) 130, an emission layer (EML) 135, a hole blocking layer (HBL) 140, an electron transport layer (ETL) 145, an electron injection layer (EIL) 150, a protective layer 155, a cathode 160, and a blocking layer 170. The cathode 160 is a composite cathode having a first conductive layer 162 and a second conductive layer 164. Device 100 can be fabricated by sequentially depositing the layers. The properties and functions of these various layers, as well as the example materials, are described in more detail in columns 6-10 of US 7,279,704, which is incorporated herein by reference.

[0546] Further examples of each of these layers are available. For instance, a flexible and transparent substrate-anode combination is disclosed in U.S. Patent No. 5,844,363, which is incorporated herein by reference in its entirety. An example of a p-doped hole transport layer is m-MTDATA doped with F4-TCNQ in a 50:1 molar ratio, as disclosed in U.S. Patent Application Publication No. 2003 / 0230980, which is incorporated herein by reference in its entirety. Examples of luminescent and host materials are disclosed in U.S. Patent No. 6,303,238 to Thompson et al., which is incorporated herein by reference in its entirety. An example of an n-doped electron transport layer is BPhen doped with Li in a 1:1 molar ratio, as disclosed in U.S. Patent Application Publication No. 2003 / 0230980, which is incorporated herein by reference in its entirety. Examples of cathodes, comprising composite cathodes having a thin layer of metal (e.g., Mg:Ag) having an overlying transparent, conductive, sputtered ITO layer, are disclosed in their entirety in U.S. Patent Nos. 5,703,436 and 5,707,745, which are incorporated herein by reference in their entirety. Theories and uses of barrier layers are described in more detail in U.S. Patent No. 6,097,147 and U.S. Patent Application Publication No. 2003 / 0230980, which are incorporated herein by reference in their entirety. Examples of implantation layers are provided in U.S. Patent Application Publication No. 2004 / 0174116, which is incorporated herein by reference in its entirety. Descriptions of protective layers can be found in U.S. Patent Application Publication No. 2004 / 0174116, which is incorporated herein by reference in its entirety.

[0547] Figure 2 An inverted OLED 200 is shown. The device includes a substrate 210, a cathode 215, an emitter layer 220, a hole transport layer 225, and an anode 230. The device 200 can be fabricated by sequentially depositing these layers. Because the most common OLED configuration has a cathode disposed above the anode, and the device 200 has a cathode 215 disposed below the anode 230, the device 200 can be referred to as an "inverted" OLED. Materials similar to those described with respect to device 100 can be used in the corresponding layers of the device 200. Figure 2 Provide an example of how some layers can be omitted from the structure of device 100.

[0548] Figure 1 and 2The simple layered structures described herein are provided by way of non-limiting examples, and it should be understood that embodiments of this disclosure can be used in conjunction with a variety of other structures. The specific materials and structures described are exemplary in nature, and other materials and structures can be used. Functional OLEDs can be obtained by combining the various layers described in different ways, or the layers can be omitted entirely based on design, performance, and cost factors. Other layers not specifically described may also be included. Materials other than those specifically described may be used. Although many examples provided herein describe various layers as comprising a single material, it should be understood that combinations of materials, such as mixtures of host and dopant, or more generally, mixtures, may be used. Furthermore, the layers may have various sublayers. The names given to the various layers herein are not intended to be strictly limiting. For example, in device 200, hole transport layer 225 transports holes and injects holes into emitter layer 220, and may be described as a hole transport layer or a hole injection layer. In one embodiment, an OLED may be described as having an “organic layer” disposed between a cathode and an anode. This organic layer may comprise a single layer, or may further comprise, for example, regarding Figure 1 and 2 Multiple layers of the different organic materials mentioned above.

[0549] Structures and materials not specifically described can also be used, such as OLEDs (PLEDs) containing polymeric materials, as disclosed in, for example, U.S. Patent No. 5,247,190 to Friend et al., which is incorporated herein by reference in its entirety. By another example, OLEDs with a single organic layer can be used. OLEDs can be stacked, for example, as described in, U.S. Patent No. 5,707,745 to Forrest et al., which is incorporated herein by reference in its entirety. OLED structures can be deviated from... Figure 1 and 2 The simple layered structure described herein. For example, the substrate may include angled reflective surfaces to improve out-coupling, such as the tabletop structure described in U.S. Patent No. 6,091,195 to Forrest et al., and / or the recessed structure described in U.S. Patent No. 5,834,893 to Bulovic et al., which are incorporated herein by reference in their entirety.

[0550] Unless otherwise specified, any of the layers in the various embodiments may be deposited by any suitable method. For organic layers, preferred methods include thermal evaporation, inkjet printing (as described in U.S. Patent Nos. 6,013,982 and 6,087,196, which are incorporated herein by reference in their entirety), organic vapor deposition (OVPD) (as described in U.S. Patent No. 6,337,102 by Forrest et al., which are incorporated herein by reference in their entirety), and deposition via organic vapor jet printing (OVJP, also known as organic vapor jet deposition (OVJD)) (as described in U.S. Patent No. 7,431,968, which is incorporated herein by reference in its entirety). Other suitable deposition methods include spin coating and other solution-based processes. Solution-based processes are preferably performed in a nitrogen or inert atmosphere. For other layers, preferred methods include thermal evaporation, sputtering, chemical vapor deposition, atomic layer deposition, and electron beam deposition. Preferred patterning methods include patterning via mask deposition, photolithography, and cold soldering (as described in U.S. Patents 6,294,398 and 6,468,819, which are incorporated herein by reference in their entirety) and some of the methods associated with deposition methods such as inkjet and organic vapor jet printing (OVJP). Other methods may also be used. The material to be deposited may be modified to suit a particular deposition method. For example, branched or unbranched substituents, preferably containing at least three carbons, such as alkyl and aryl groups, may be used in small molecules to enhance their solution handling ability. Substituents having 20 or more carbons may be used, with 3 to 20 carbons being a preferred range. Materials with asymmetric structures may have better solution handling ability than materials with symmetric structures because asymmetric materials may have a lower tendency to recrystallize. Dendritic polymer substituents may be used to enhance the solution handling ability of small molecules.

[0551] The device manufactured according to embodiments of this disclosure may optionally further include a barrier layer. One use of the barrier layer is to protect the electrodes and organic layers from damage caused by exposure to harmful substances in an environment including moisture, vapors, and / or gases. The barrier layer may be deposited above, below, or adjacent to a substrate or electrode, or above any other part of the device, including edges. The barrier layer may comprise a single layer or multiple layers. The barrier layer can be formed using various known chemical vapor deposition techniques and may comprise compositions having a single phase and compositions having multiple phases. Any suitable material or combination of materials may be used for the barrier layer. Inorganic or organic compounds, or both, may be incorporated into the barrier layer. Preferred barrier layers comprise multiple alternative layers of materials including: polymeric and nonpolymeric materials; organic and inorganic materials; or mixtures of polymeric and nonpolymeric materials, an example of which is described in U.S. Patent No. 7,968,146, PCT Patent Application Nos. PCT / US2007 / 023098 and PCT / US2009 / 042829, which are incorporated herein by reference in their entirety.

[0552] The apparatus manufactured according to embodiments of this disclosure can be incorporated into a wide variety of electronic component modules (or units), which can be incorporated into a variety of electronic products or intermediate components. Examples of such electronic products or intermediate components include displays, lighting devices (such as discrete light source devices or lighting panels), etc., which can be utilized by end-user product manufacturers. The electronic component module may optionally include driving electronics and / or a power supply. The apparatus manufactured according to embodiments of this disclosure can be incorporated into a wide variety of consumer products having one or more electronic component modules (or units) incorporated therein. A consumer product incorporating an OLED is disclosed, wherein the OLED includes compounds of this disclosure in its organic layer. The consumer product should include any kind of product containing one or more light sources and / or one or more of some type of visual display. Examples of the consumer products described include flat panel displays, curved displays, computer monitors, medical monitors, televisions, billboards, lights for internal or external lighting and / or signaling, head-up displays, fully transparent or partially transparent displays, flexible displays, rollable displays, foldable displays, stretchable displays, laser printers, telephones, cellular phones, tablet computers, phablets, personal digital assistants (PDAs), wearable devices, laptop computers, digital cameras, camcorders, viewfinders, microdisplays (displays with a diagonal of less than 2 inches), 3D displays, virtual reality or augmented reality displays, vehicles, video walls comprising multiple tiled displays, theater or stadium screens, phototherapy devices, and signage. Various control mechanisms, including passive and active matrices, can be used to control the devices manufactured according to this disclosure. Many of the devices are intended for use in temperature ranges comfortable for humans, such as 18°C ​​to 30°C, and more preferably at room temperature (20-25°C), but can be used outside this temperature range (e.g., -40°C to +80°C).

[0553] Further details regarding OLEDs and the definitions described above can be found in U.S. Patent No. 7,279,704, which is incorporated herein by reference in its entirety.

[0554] The materials and structures described herein can be applied to devices other than OLEDs. For example, other optoelectronic devices such as organic solar cells and organic photodetectors can utilize the materials and structures described herein. More generally, organic devices such as organic transistors can utilize the materials and structures described herein.

[0555] In some embodiments, the OLED has one or more features selected from the group consisting of: flexible, rollable, foldable, stretchable, and bendable. In some embodiments, the OLED is transparent or translucent. In some embodiments, the OLED further comprises a layer including carbon nanotubes. In some embodiments, the OLED further comprises one or more quantum dots. Such quantum dots may be in the emission layer or in other functional layers, such as conversion layers.

[0556] In some embodiments, the OLED comprises an RGB pixel arrangement or a white pixel arrangement with a color filter. In some embodiments, the OLED is a mobile device, a handheld device, or a wearable device. In some embodiments, the OLED is a display panel with a diagonal of less than 10 inches or an area of ​​less than 50 square inches. In some embodiments, the OLED is a display panel with a diagonal of at least 10 inches or an area of ​​at least 50 square inches. In some embodiments, the OLED is a lighting panel.

[0557] D. Other materials used in OLEDs

[0558] The materials described herein are various examples of materials that can be used in specific layers in OLEDs. They can also be used in combination with a wide variety of other materials present in the device. For example, the emission dopants disclosed herein can be used by the emission dopants themselves in the EML, or in combination with a wide variety of other emitters, hosts, transport layers, barrier layers, implantation layers, electrodes, and other layers that may be present. The materials described or mentioned below are non-limiting examples of materials that can be used in combination with the compounds and devices disclosed herein, and those skilled in the art can readily consult the literature to identify other materials that can be used in combination.

[0559] a) Conductive dopants:

[0560] Charge transport layers can be doped with conductive dopants to substantially alter their charge carrier density, which in turn changes their conductivity. Conductivity is increased by generating charge carriers in the matrix material and, depending on the type of dopant, can also achieve changes in the Fermi level of the semiconductor. Hole transport layers can be doped with p-type conductive dopants, and n-type conductive dopants are used in electron transport layers. In some embodiments, the conductive dopant comprises at least one chemical moiety selected from the group consisting of: cyano, fluorinated aryl or heteroaryl, fluorinated alkyl or cycloalkyl, alkylene, heteroaryl, amide, benzodithiophene, and highly conjugated heteroaryl extended by acyclic double bonds.

[0561] b) HIL / HTL:

[0562] The hole injection / transport materials used in this disclosure are not particularly limited, and any compound may be used, provided that the compound is commonly used as a hole injection / transport material. Examples of materials include (but are not limited to): phthalocyanine or porphyrin derivatives; aromatic amine derivatives; indole-carbazole derivatives; polymers containing fluorinated hydrocarbons; polymers with conductive dopants; conductive polymers, such as PEDOT / PSS; self-assembled monomers derived from compounds such as phosphonic acids and silane derivatives; and metal oxide derivatives, such as MoO. x p-type semiconductive organic compounds, such as 1,4,5,8,9,12-hexaazatriphenylhexacarbonitrile; metal complexes; and crosslinkable compounds.

[0563] Examples of aromatic amine derivatives used for HIL or HTL include (but are not limited to) the following general structures:

[0564]

[0565] Ar 1 To Ar 9 Each of these is selected from the group consisting of, for example, aromatic hydrocarbon cyclic compounds such as: benzene, biphenyl, terphenyl, triphenylene, naphthalene, anthracene, fenene, fluorene, pyrene, Perylene and azurite; the group consisting of, for example, aromatic heterocyclic compounds such as: dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridinylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxtriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxthiazine, oxadiazine, indole, benzimidazole, indazole, inoxazine, benzoxazole, benziisoxazole, benzothiazole, quinoline, isoquinoline, zoline, quinazoline Quinoxaline, naphthidine, phthalazine, pteridine, oxanthracene, acridine, phenazine, phenothiazine, phenoxazine, benzofuranopyridine, furanodipyridine, benzothiophenopyridine, thiophenodipyridine, benzoselenophenepyridine, and selenophenodipyridine; and the group consisting of 2 to 10 cyclic structural units, said cyclic structural units being groups of the same or different types selected from aromatic hydrocarbon cyclic groups and aromatic heterocyclic groups and bonded to each other directly or via at least one of oxygen, nitrogen, sulfur, silicon, phosphorus, boron, chain structural units, and aliphatic cyclic groups. 1 To Ar 9 Each of them may be unsubstituted or may be substituted by the general substituents described above, and any two substituents may be joined or fused together to form a ring.

[0566] In some embodiments, each Ar 1 To Ar 9 Independently includes portions selected from the following groups:

[0567]

[0568] Where k is an integer from 1 to 20; X 101 To X 108 It is C or N; Z 101 It is C, N, O, or S.

[0569] Examples of metal complexes used in HIL or HTL include, but are not limited to, the following general formula:

[0570] Met is a metal with an atomic weight greater than 40; (Y 101 -Y 102 ) is a bidentate ligand, Y 101 and Y 102 The coordinating atoms are independently selected from C, N, O, P, and S; L 101 It is another ligand; k' is an integer value from 1 to the maximum number of ligands that can bind to the metal; and k'+k ” It is the maximum number of ligands that can bind to metal.

[0571] In some embodiments, (Y) 101 -Y 102 (Y) is a 2-phenylpyridine or 2-phenylimidazole derivative. In some embodiments, (Y) 101 -Y 102 Met is a carbene ligand. In some embodiments, Met is selected from Ir, Pt, Pd, Os, Cu, and Zn. In some embodiments, the metal complex has a relative... + The minimum oxidation potential in solution with / Fc coupling is less than about 0.6V.

[0572] In some embodiments, the HIL / HTL material is selected from the group consisting of: phthalocyanine and porphyrin compounds, starburst triarylamine, CF x Fluorinated hydrocarbon polymers, conductive polymers (e.g., PEDOT:PSS, polyaniline, polythiophene), phosphonic acids and silane SAMs, triarylamines or polythiophene polymers containing conductive dopants, organic compounds containing conductive inorganic compounds (such as molybdenum oxide and tungsten oxide), n-type semiconductive organic complexes, organometallic complexes, crosslinkable compounds, polythiophene-based polymers and copolymers, triarylamines, triarylamines containing spirofluorene cores, arylamine carbazole compounds, triarylamines containing (di)benzothiophene / (di)benzofuran, indole-carbazole, isoindole compounds, and metal carbene complexes.

[0573] c)EBL:

[0574] An electron blocking layer (EBL) can be used to reduce the number of electrons and / or excitons leaving the emitter layer. The presence of such a blocking layer in a device can result in generally higher efficiency and / or longer lifetime compared to similar devices lacking a blocking layer. Furthermore, the blocking layer can be used to confine emission to a desired area of ​​the OLED. In some embodiments, the EBL material has a higher LUMO (closer to vacuum level) and / or a higher triplet energy compared to one or more emitters closest to the EBL interface. In some embodiments, the compound used in the EBL contains at least one carbazole group and / or at least one arylamine group. In some embodiments, the HOMO level of the compound used in the EBL is shallower than the HOMO levels of one or more of the host molecules in the EML. In some embodiments, the compound used in the EBL contains the same molecule or the same functional groups as those used in one of the host molecules described below.

[0575] d) Main body:

[0576] The light-emitting layer of the organic EL device disclosed herein preferably contains at least a light-emitting material as a dopant and a host material. Examples of the host material are not particularly limited, and any metal complex or organic compound can be used, as long as the host does not completely quench the emission of the dopant.

[0577] Examples of metal complexes used as the host preferably have the following general formula:

[0578]

[0579] Where Met is a metal; (Y) 103 -Y 104 ) is a bidentate ligand, Y 103 and Y 104 The coordinating atoms are independently selected from C, N, O, P, and S; L 101 It is another ligand; k' is an integer value from 1 to the maximum number of ligands that can be bound to the metal; and k'+k” is the maximum number of ligands that can be bound to the metal.

[0580] In some embodiments, the metal complex is:

[0581]

[0582] (ON) is a bidentate ligand of a metal that coordinates with O and N atoms.

[0583] In some embodiments, Met is selected from Ir and Pt. In another embodiment, (Y 103 -Y 104 ) is a carbaene ligand.

[0584] In some embodiments, the host compound contains at least one selected from the group consisting of, for example, aromatic hydrocarbon cyclic compounds such as: benzene, biphenyl, terphenyl, triphenylene, tetraphenylene, naphthalene, anthracene, fenene, fluorene, pyrene, etc. Perylene and azurite; the group consisting of, for example, aromatic heterocyclic compounds such as: dibenzothiophene, dibenzofuran, dibenzoselenene, furan, thiophene, benzofuran, benzothiophene, benzoselenene, carbazole, indolocarbazole, pyridinylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxtriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxthiazine, Oxadiazine, indole, benzimidazole, indazole, indoxazine, benzoxazole, benziisoxazole, benzothiazole, quinoline, isoquinoline, cinnamoline, quinazoline, quinoxaline, naphthidine, phthalazine, pteridine, oxanthracene, acridine, phenazine, phenothiazine, phenothiazine, aza-dibenzothiophene, aza-dibenzofuran, aza-dibenzoselenophene, aza-carbazole, aza-indolocarbazole, aza-triphenylene, aza-tetraphenylene, 5λ 2 -Benzo[d]benzo[4,5]imidazo[3,2-a]imidazolium, 5,9-dioxa-13b-boronazonaphtho[3,2,1-de]anthracene; and groups consisting of 2 to 10 cyclic structural units, said cyclic structural units being groups of the same or different types selected from aromatic hydrocarbon cyclic groups and aromatic heterocyclic groups and bonded to each other directly or via at least one of oxygen, nitrogen, sulfur, silicon, phosphorus, boron, chain structural units, and aliphatic cyclic groups. Each option within each group may be unsubstituted or may be substituted by universal substituents as described herein or may be further fused.

[0585] In some embodiments, the host compound comprises at least one portion selected from the group consisting of:

[0586] Where k is an integer between 0 and 20 or between 1 and 20. X 101 To X 108 Independently selected from C or N. Z 101 and Z 102 It is independently selected from C, N, O, or S.

[0587] In some embodiments, the host material is selected from the group consisting of: arylcarbazole, metal 8-hydroxyquinoline compounds (e.g., alq3, balq), metal phenoxybenzothiazole compounds, conjugated oligomers and polymers (e.g., polyfluorene), aromatic fused rings, zinc complexes, and based on... Compounds, aryltriphenylene compounds, polyfused heteroaryl compounds, donor-acceptor molecules, dibenzofuran / dibenzothiophene compounds, polymers (e.g., PVK), spirofluorene compounds, spirofluorene-carbazole compounds, indole-carbazole, 5-membered electron-deficient heterocycles (e.g., triazoles, oxadiazoles), tetraphenylene complexes, metal phenoxypyridine compounds, metal coordination complexes (e.g., Zn, Al containing N^N ligands), dibenzothiophene / dibenzofuran-carbazole compounds, silicon / germanium aryl compounds, aryl benzoyl esters, non-conjugated carbazoles, aza-carbazole / dibenzofuran / dibenzothiophene compounds, and high triplet state organometallic complexes (e.g., metal-carbaene complexes).

[0588] e) Emitter material in EML:

[0589] One or more emitter materials may be used in conjunction with the compounds or devices disclosed herein. The emitter materials may be emittant or non-emittent in the current devices described herein. Examples of emitter materials are not particularly limited, and any compound may be used as long as it is capable of generating emission in a conventional OLED device. Examples of suitable emitter materials include, but are not limited to, compounds capable of generating emission via phosphorescence, non-delayed fluorescence, delayed fluorescence (especially thermally activated delayed fluorescence, i.e., TADF (also known as E-type delayed fluorescence)), triplet-triplet annihilation, or combinations thereof.

[0590] In some embodiments, the emitter material has the formula M(L) 1 ) x (L 2 ) y (L 3 ) z ;

[0591] Where L 1 L 2 and L 3 They can be the same or different;

[0592] Where x is 1, 2, or 3;

[0593] Where y is 0, 1, or 2;

[0594] Where z is 0, 1, or 2;

[0595] Where x+y+z is the oxidation state of the metal M;

[0596] Where L 1 Select the group consisting of structures from the following list of ligands:

[0597]

[0598]

[0599]

[0600] Each L 2 and L 3 Independently select groups of structures from the list of free and ligands. in:

[0601] M is selected from the following groups: Ir, Rh, Re, Ru, Os, Pt, Pd, Zn, Au, Ag, and Cu;

[0602] T can be freely selected from the following groups: B, Al, Ga, and In;

[0603] K 1' It is a direct key or a selection of the following groups: NR e PR e , O, S and Se;

[0604] Each Y 1 To Y 15 Independently select groups composed of free carbon and nitrogen;

[0605] Y' selects from the following groups: BR e NR e PR e ,O,S,Se,C=O,S=O,SO2,CR e R f SiR e R f and GeR e R f ;

[0606] Each R a R b R c and R d It can independently represent monosubstituted to the maximum possible number of substitutions or no substitution;

[0607] Each R a1 R b1 R c1 R d1 R a R b R c R d R e and R f Independently, it is hydrogen or a substituent selected from the group of universal substituents as defined herein; and

[0608] Any two of the substituents can fused or joined to form a ring or a polydentate ligand.

[0609] In some embodiments, the emitter material is selected from the group consisting of the following dopant group 1:

[0610]

[0611]

[0612]

[0613]

[0614] in

[0615] X 96 To X 99 Each of them is independently C or N;

[0616] Each Y 100 Independently select the groups composed of NR", O", S and Se;

[0617] R 10a R 20a R 30a R 40a and R 50a Each of these terms independently represents monosubstituted, at most maximum substituted, or unsubstituted.

[0618] R, R', R ” R 10a R 11a R 12a R 13a R 20a R 30a R 40a R 50a R 60 R 70 R 97 R 98 and R 99 Each of them is independently hydrogen or a substituent selected from the group of general substituents as defined herein; any two substituents may join or fuse to form a ring.

[0619] In some embodiments, the emitter material is selected from the group consisting of the following dopant group 2:

[0620]

[0621]

[0622]

[0623]

[0624]

[0625]

[0626]

[0627]

[0628] in:

[0629] Each Y 100 Independently select the groups composed of NR", O", S and Se;

[0630] L is independently selected from the following groups: direct bond, BR”, BR”R”', NR”, PR”, O, S, Se, C=O, C=S, C=Se, C=NR”, C=CR”R”', S=O, SO2, CR”, CR”R”', SiR”R”', GeR”R”', alkyl, cycloalkyl, aryl, heteroaryl and combinations thereof;

[0631] X 100 and X 200 Each time it appears, select from the following groups: O, S, Se, NR” and CR”R”';

[0632] Each R A” R B” R C” R D” R E” and R F” Independently represent monosubstituted, at most maximum substituted, or unsubstituted;

[0633] R, R', R”, R”', R A1' R A2' R A” R B” R C” R D” R E” R F” R G” R H” R I” R J” R K” R L” R M” and R N” Each of them is independently hydrogen or a substituent selected from the group of general substituents as defined herein; and any two substituents may join or fuse to form a ring.

[0634] In some embodiments of dopant groups 1 and 2 above, each unsubstituted aromatic carbon atom may be replaced by N to form a nitrogen heterocycle. In some embodiments, the maximum number of N atoms in a ring is 1 or 2. In some embodiments of dopant group 2 above, each Pt atom in the formula may be replaced by a Pd atom.

[0635] In some embodiments of OLEDs, the delayed fluorescence material comprises at least one donor group and at least one acceptor group. In some embodiments, the delayed fluorescence material is a metal complex. In some embodiments, the delayed fluorescence material is a non-metallic complex. In some embodiments, the delayed fluorescence material is a Zn, Cu, Ag, or Au complex.

[0636] In some embodiments of OLEDs, the delayed fluorescence material has the formula M(L 5 (L) 6 ), where M is Cu, Ag, or Au, L 5 and L 6 Different, and L 5 and L 6 Choose independently from the following groups:

[0637]

[0638]

[0639]

[0640] Where A 1 –A 9 Each is independently selected from C or N;

[0641] Each R P R Q and R U Independently represent monosubstituted, at most maximum substituted, or unsubstituted;

[0642] Each R P R P R U R SA R SB R RA R RB R RC R RD R RE and R RF Substituents are independently hydrogen or selected from the group of general substituents as defined herein; any two substituents may join or fuse to form a ring.

[0643] In some embodiments of the OLED, the delayed fluorescence material comprises at least one donor portion selected from the group consisting of:

[0644]

[0645] Where Y T Y U Y V and Y W Each of the following groups is selected independently: B, C, Si, Ge, N, P, O, S, Se, C=O, S=O, and SO2.

[0646] In some of the above embodiments, any carbon ring atom in each benzene ring of any of the above structures, up to a total of up to three carbon ring atoms, together with their substituents, may be replaced by N.

[0647] In some embodiments, the delayed fluorescence material comprises at least one acceptor moiety selected from the group consisting of: nitrile, isonitrile, borane, fluoride, pyridine, pyrimidine, pyrazine, triazine, aza-carbazole, aza-dibenzothiophene, aza-dibenzofuran, aza-dibenzoselenophene, aza-triphenylene, imidazole, pyrazole, oxazole, thiazole, isoxazole, isothiazole, triazole, thiadiazole, and oxadiazole. In some embodiments, the acceptor moiety and donor moiety as described herein may be directly linked via a conjugated linker group or a non-conjugated linker group (such as sp...). 3 (Carbon or silicon atoms) are linked together.

[0648] In some embodiments, the fluorescent material comprises at least one chemical moiety selected from the group consisting of:

[0649]

[0650] Where Y F Y G Y H and Y I Each of the following groups can be selected independently: B, C, Si, Ge, N, P, O, S, Se, C=O, S=O, and SO2;

[0651] Where X F and X G Each group is independently selected from the groups composed of C and N.

[0652] In some of the above embodiments, any carbon ring atom in each benzene ring of any of the above structures, up to a total of up to three carbon ring atoms, together with their substituents, may be replaced by N.

[0653] f)HBL:

[0654] Hole blocking layers (HBLs) can be used to reduce the number of holes and / or excitons leaving the emitter layer. The presence of such blocking layers in a device can result in generally higher efficiency and / or longer lifetime compared to similar devices lacking a blocking layer. Furthermore, blocking layers can be used to confine emission to the desired area of ​​the OLED. In some embodiments, the HBL material has a lower HOMO (farthest from vacuum level) and / or higher triplet energy compared to one or more emitters closest to the HBL interface.

[0655] In some embodiments, the compounds used in HBL contain the same molecules or the same functional groups as those used in the main body described above.

[0656] In some embodiments, the compound used in HBL comprises at least one of the following portions selected from the group consisting of:

[0657] Where k is an integer from 1 to 20; L 101 It is another ligand, and k' is an integer from 1 to 3.

[0658] g)ETL:

[0659] An electron transport layer (ETL) may comprise a material capable of transporting electrons. The ETL may be intrinsic (undoped) or doped. Doping can be used to enhance conductivity. Examples of ETL materials are not particularly limited, and any metal complex or organic compound may be used, provided it is typically used for electron transport.

[0660] In some embodiments, the compounds used in the ETL contain at least one of the following portions in their molecules:

[0661] and fullerenes; where k is an integer from 1 to 20, X 101 To X 108 Selected from C or N; Z 101 Choose a group consisting of C, N, O, and S.

[0662] In some embodiments, the metal complexes used in the ETL contain, but are not limited to, the following general formula:

[0663]

[0664] Wherein (ON) or (NN) are bidentate ligands of metals that coordinate with atoms O, N, or N,N; L 101 It is another ligand; k' is an integer value from 1 to the maximum number of ligands that can be bonded to the metal.

[0665] In some embodiments, the ETL material is selected from the group consisting of: anthracene-benzimidazole compounds, azirtriene derivatives, anthracene-benzothiazole compounds, metal 8-hydroxyquinoline compounds, metal hydroxybenzoquinoline compounds, bathocuprine compounds, 5-membered electron-deficient heterocycles (e.g., triazoles, oxadiazoles, imidazoles, benzimidazoles), thiophene compounds, arylborane compounds, fluorinated aromatic compounds, fullerenes (e.g., C60), triazine complexes, and Zn(N^N) complexes.

[0666] h) Charge Generation Layer (CGL)

[0667] In tandem or stacked OLEDs, the conduction layer (CGL) plays a fundamental role in performance. It consists of an n-doped layer and a p-doped layer, respectively, for injecting electrons and holes. Electrons and holes are supplied by the CGL and the electrodes. Electrons and holes consumed in the CGL are refilled by electrons and holes injected from the cathode and anode, respectively; subsequently, the bipolar current gradually reaches a steady state. Typical CGL materials include n- and p-conductive dopants used in the transport layer.

[0668] In any of the compounds disclosed herein, hydrogen atoms may be partially or fully deuterated. The minimum amount of deuterated hydrogen in a compound is selected from the group consisting of: 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, and 100%. As used herein, the percentage of deuteration has its general meaning and includes the percentage of all possible hydrogen and deuterium atoms replaced by deuterium atoms. In some embodiments, the deuterium atom is attached to an aromatic ring. In some embodiments, the deuterium atom is attached to a saturated carbon atom, such as an alkyl or cycloalkyl carbon atom. In some other embodiments, the deuterium atom is attached to a heteroatom, such as a Si or Ge atom.

[0669] It should be understood that the various embodiments described herein are merely examples and are not intended to limit the scope of the invention. For instance, many of the materials and structures described herein can be substituted with other materials and structures without departing from the spirit of the invention. The claimed invention may therefore include variations of the specific examples and preferred embodiments described herein, as will be apparent to those skilled in the art. It should be understood that various theories regarding why the invention works are not intended to be limiting.

[0670] E. Experimental Section

[0671] Material synthesis

[0672] Synthesis of Compound 3

[0673]

[0674] To 2-(3-methoxydibenzo[b,d]furan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxane-1 (10.0 g, 1 equivalent, 30.85 mmol), 1-bromo-3-chloro-2-fluorobenzene 2 (7.11 g, 1.1 equivalent, 33.93 mmol), SPhos (2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl) (633.2 mg, 0.05 equivalent, 1.542 mmol) and SPhos A mixture of Pd(crotonyl)Cl((1,2,3-η)-2-buten-1-yl]chloro[dicyclohexyl(2',6'-dimethoxy[1,1'-biphenyl]-2-yl)phosphine-κP]palladium) (962 mg, 0.05 equivalents, 1.542 mmol) in acetonitrile (100 mL) was added to an aqueous solution of K2CO3 (12.8 g, 3 equivalents, 92.54 mmol) in water (25 mL). The mixture was degassed with nitrogen for 10 min and then heated to 65 °C overnight (about 12 h). The mixture was diluted with water (200 mL) and the aqueous layer was extracted with ethyl acetate (EtOAc) (3 x 100 mL). The combined organic extracts were washed with brine (150 mL), dried over Na2SO4, filtered, and concentrated under vacuum. The crude product was purified by silica gel chromatography to give 2-(3-chloro-2-fluorophenyl)-3-methoxydibenzo[b,d]furan 3 (9.25 g, 27 mmol, 86%) as a white solid.

[0675] Synthesis of Compound 4

[0676]

[0677] At 0 °C, BBr3 (47.90 mL, 1,000 mol, 1.8 equivalence, 47.90 mmol) in a solution of 2-(3-chloro-2-fluorophenyl)-3-methoxydibenzo[b,d]furan3 (9.25 g, 1 equivalent, 26.61 mmol) in dry dichloromethane (DCM) (100 mL) was added dropwise. The mixture was stirred at 0 °C for 1 hour and then at 25 °C for 3 hours. The mixture was placed in an ice bath and quenched by slow addition of cold water (200 mL). The aqueous layer was extracted with DCM (3 x 200 mL). The combined organic extracts were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under vacuum to give the desired product 2-(3-chloro-2-fluorophenyl)dibenzo[b,d]furan-3-ol 4 (8.700 g, 26 mmol, 96%) as a light brown solid.

[0678] Synthesis of Compound 5

[0679]

[0680] NBS (N-bromosuccinimide) (4.95 g, 1.05 equivalent, 27.80 mmol) was added to a solution of 3-(3-chloro-2-fluorophenyl)dibenzo[b,d]furan-2-ol 4 (9.00 g, 1 equivalent, 26.48 mmol) in ethanol (100 mL) at 0 °C. The resulting reaction mixture was stirred at 0 °C for 30 min and then at 25 °C for 3 h. The mixture was diluted with water (200 mL), and the aqueous layer was extracted with ethyl acetate (EtOAc) (3 x 150 mL). The combined organic extracts were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under vacuum. The crude product was purified by silica gel chromatography to give 1-bromo-3-(3-chloro-2-fluorophenyl)dibenzo[b,d]furan-2-ol 5 (10.0 g, 25 mmol, 95%) as a pale yellow solid.

[0681] Synthesis of Compound 6

[0682]

[0683] Potassium carbonate (10.4 g, 3 equivalents, 75.07 mmol) was added to a solution of 1-bromo-3-(3-chloro-2-fluorophenyl)dibenzo[b,d]furan-2-ol 5 (10.0 g, 1 equivalent, 25.02 mmol) in NMP (N-methyl-2-pyrrolidone) (200 mL), and the reaction mixture was stirred overnight at 100 °C (about 12 h). The reaction mixture was cooled and water (200 mL) was slowly added with stirring, and the resulting solution was allowed to stand for 30 min. The solution was filtered and washed several times with water to remove excess NMP. The white solid was placed in a DCM / CHCl3 mixture (1:2), dried with Na2SO4, and concentrated to dryness under reduced pressure. The solid was ground in MeOH for 2 h, then filtered and dried under vacuum overnight to give a pure, white solid of the desired product (6).

[0684] Synthesis of Compound 1 of the present invention

[0685]

[0686] Example 1 of the present invention can be synthesized using the scheme described above. The coupling reaction of 6 with 3,6-di-tert-butyl-9H-carbazole yields 7, which can be converted to 8 by the Miyaura borylation of 7 followed by coupling with 2-chloro-4-(2,2-dimethylpropyl-1,1-d2)-5-(methyl-d3)pyridine. The linkage reaction of compound 8 with dimer 9 produces compound 1 of the present invention as the desired product.

[0687] Synthesis of Compound 4 of the present invention

[0688]

[0689] Example 4 of the present invention can be synthesized using the scheme described above. The coupling reaction of 6 with [1,1'-diphenyl]-4-ylboronic acid yields 10, which can be converted to 11 by borylation of 10 followed by coupling with 2-chloro-4-(2,2-dimethylpropyl-1,1-d2)-5-(methyl-d3)pyridine. The linkage reaction of compound 11 with dimer 9 produces compound 4 of the present invention as the desired product.

[0690] Synthesis of Compound 7 of the present invention

[0691]

[0692] Example 7 of the present invention can be synthesized using the scheme described above. The coupling reaction of 6 with 2-(3,5-diisopropyl-[1,1'-biphenyl]-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane yields 12, which can be converted to 13 by the borylation of 12 followed by coupling with 2-chloro-4-(2,2-dimethylpropyl-1,1-d2)-5-(methyl-d3)pyridine. The linkage reaction of compound 13 with dimer 9 produces compound 7 of the present invention as the desired product.

[0693] Synthesis of Compound 19 of the present invention

[0694]

[0695] Example 19 of the present invention can be synthesized via the scheme described above. The coupling reaction of 6 with 2-(3,5-di-tert-butylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane yields 14, which can be converted to 15 by borylation of 14 followed by coupling with 2-chloro-4-(2,2-dimethylpropyl-1,1-d2)-5-(methyl-d3)pyridine. The linkage reaction of compound 15 with dimer 9 produces compound 19 of the present invention as the desired product.

[0696] Synthesis of Compound 20 of the present invention

[0697]

[0698] Example 20 of the present invention can be synthesized via the scheme described above. The coupling reaction of 6 with 2-([1,1':3',1”-terphenyl]-5'-yl)-4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane yields 16, which can be converted to 17 by the borylation of 16 followed by coupling with 2-chloro-4-(2,2-dimethylpropyl-1,1-d2)-5-(methyl-d3)pyridine. The linkage reaction of compound 17 with dimer 9 produces compound 20 of the present invention as the desired product.

[0699] Synthesis of Compound 19

[0700]

[0701] Under nitrogen atmosphere, 1-bromo-4-iodo-2-methoxybenzene 18 (60.0 g, 1.0 equivalent, 192 mmol) was dissolved in dry DCM (600 mL) and cooled to 0 °C. Dichloro(methoxy)methane (28.7 g, 22.5 mL, 1.3 equivalent, 249 mmol) was then added in portions over 2 minutes, followed by the addition of TiCl4 (1 M in DCM, 403 mL, 2.1 equivalent, 403 mmol) in portions over 40 minutes (keeping the internal temperature below 5 °C). The reaction mixture was warmed to room temperature overnight with stirring, cooled to 0 °C, and then quenched over 15 minutes by careful addition of 1 M HCl aqueous solution (500 mL). The layers were separated, and the aqueous layer was extracted with DCM (2 x 600 mL). The combined organic extracts were dried over Na₂SO₄, filtered, concentrated under vacuum, and then azeotropically dried with acetonitrile (MeCN) to give a pale purple solid, 67.2 g. The pale purple solid was suspended in MeCN (50 ml) and stirred at room temperature for 2 hours. The solid was filtered off and dried under vacuum to give 5-bromo-2-iodo-4-methoxybenzaldehyde 19 (83%, 59.3 g), which was a pale gray solid.

[0702] Synthesis of Compound 20

[0703]

[0704] 5-Bromo-2-iodo-4-methoxybenzaldehyde 19 (50.3 g, 1.0 equivalent, 143 mmol), 5-chloro-2-formylphenyl)boronic acid (29.0 g, 1.1 equivalent, 157 mmol), and K₂CO₃ (75.2 g, 3.8 equivalent, 544 mmol) were suspended in dry dimethyl sulfoxide (DMSO) (840 mL) and bubbled under nitrogen for 25 min. PdCl₂dppf.DCM (dichlorobis(triphenylphosphine)palladium(II)dichloromethane solvate) (11.7 g, 0.1 equivalent, 14.3 mmol) was added, and the reaction mixture was heated to 80 °C for 2.5 h. The reaction mixture was cooled to room temperature and then diluted with methyl tert-butyl ether (MtBE) (500 mL) and water (350 mL). The resulting two-phase mixture was filtered through filter paper to remove interphase solids. The filtrate phase was separated, and the aqueous phase was extracted with MtBE (2 x 500 mL). The combined organic matter was washed with brine (2 x 300 mL), dried over MgSO4, filtered, and concentrated under vacuum to give a dark brown oil. The dark brown oil was purified by rapid column chromatography, eluting with 0–30% (1:1 EtOAc:DCM) / hexane. The purified fractions were combined and concentrated under vacuum to give 4-bromo-5'-chloro-5-methoxy-[1,1'-biphenyl]-2,2'-dicarboxaldehyde 20 (37.0 g, 0.1 mol, 72%) as a pale yellow, oily foam.

[0705] Synthesis of Compound 21

[0706]

[0707] Under nitrogen atmosphere, 22.2 g (1.0 equivalent, 61.6 mmol) of 4-bromo-5'-chloro-5-methoxy-[1,1'-biphenyl]-2,2'-dicarboxaldehyde 20 was dissolved in glacial acetic acid (AcOH) (420 mL), and the mixture was heated to 100 °C. After 5 minutes, a solution of hydrazine hydrate (4.32 g, 4.23 mL, 1.4 equivalent, 86.2 mmol) in glacial AcOH (42 mL, which dissolves at 0 °C due to strong exothermic reaction) was added dropwise, and the reaction mixture was stirred at 100 °C for 3 hours. The reaction mixture was cooled to room temperature, transferred to a beaker in an ice bath, and carefully quenched with ice-water (260 mL) for 10 minutes. Then, after 10 minutes, 650 mL of 2M NaOH aqueous solution was slowly added, and the resulting mixture was stirred at 10–15 °C for 15 minutes. The resulting solid was filtered off, washed with water (3 x 100 mL), transferred to a round-bottom flask (RBF) using DCM (300 mL) and dried under vacuum, then azeotropically dried with acetonitrile (MeCN) to give 2-bromo-6-chloro-3-methoxyphenanthrene 21 (22.2 g, 60 mmol, 98%) as a brown solid.

[0708] Synthesis of Compound 22

[0709]

[0710] Under nitrogen atmosphere, 2-bromo-6-chloro-3-methoxyphenanthrene 21 (32.8 g, 1.0 equivalent, 89.8 mmol) and (2-fluoro-3-methoxyphenyl)boronic acid (18.3 g, 1.2 equivalent, 108 mmol) were dissolved in dioxane (360 mL). Then, a solution of Na₂CO₃ (28.5 g, 3.0 equivalent, 269 mmol) in water (60 mL) was added, and the reaction mixture was bubbled thoroughly under nitrogen atmosphere for 20 minutes. Pd(PPh₃)₄ (5.19 g, 0.05 equivalent, 4.49 mmol) was added, and the reaction mixture was heated to 80 °C overnight. The reaction mixture was cooled to room temperature, diluted with water (300 mL), and stirred for 5 minutes. The mixture was extracted with DCM (600 mL), and the phases were separated. The aqueous phase was further extracted with DCM (2 x 300 mL), and the combined organic matter was washed with water (300 mL), then with saturated brine (300 mL), dried over Na₂SO₄, filtered, and concentrated under vacuum to give a dark brown oily solid, 45.1 g. The dark brown oily solid was suspended in MeCN (175 mL) and stirred overnight at room temperature. The solid was filtered off and dried under vacuum to give an orange solid, 6-chloro-2-(2-fluoro-3-methoxyphenyl)-3-methoxyphenanthrene 22 (24.3 g, 62 mmol, 69%).

[0711] Synthesis of Compound 23

[0712]

[0713] Under nitrogen atmosphere, 24.3 g (1.0 equivalent, 62.3 mmol) of 6-chloro-2-(2-fluoro-3-methoxyphenyl)-3-methoxyphenanthrene 22 was dissolved in dry DCM (350 mL) and cooled to 0 °C. BBr3 (1 M in DCM, 131 mL, 2.1 equivalent, 131 mmol) was added dropwise over 10 minutes, and the reaction mixture was slowly warmed to room temperature over 3 hours. After 15 minutes, the reaction mixture was quenched in portions in ice-cold MeOH (170 mL), and the resulting mixture was stirred for 30 minutes. The resulting dilute suspension was concentrated under vacuum to give a brown solid, which was then suspended in water (250 mL) and stirred overnight at room temperature. The solid was filtered off, washed with water (30 mL), and then with hexane (30 mL). The washed solid was dried under vacuum and then azeotropically reacted with MeCN to give a grayish-brown solid. The grayish-brown solid was suspended in MeCN (130 mL) and stirred at room temperature for 2 hours, then placed in an ice / water bath and stirred for 10 minutes. The solid was filtered off and dried under vacuum to give the first batch of 6-chloro-2-(2-fluoro-3-hydroxyphenyl)phenanthrene-3-ol 23 (10.4 g, 29 mmol, 46%) as a pale gray solid.

[0714] Synthesis of Compound 24

[0715]

[0716] Under nitrogen atmosphere, 20.9 g (1.0 equivalent, 58.08 mmol) of 6-chloro-2-(2-fluoro-3-hydroxyphenyl)phenanthrene-3-ol 23 was dissolved in dry NMP (450 mL), followed by the addition of K2CO3 (28.1 g, 3.5 equivalent, 203.3 mmol), and the reaction mixture was heated to 170 °C overnight. The reaction mixture was further heated to 190 °C for an additional 30 hours, and then cooled to room temperature. The reaction mixture was diluted with MtBE (250 mL) and water (1.2 L), and the phases were separated. The aqueous phase was extracted with MtBE (4 x 250 mL). The combined organic matter was washed with water (2 x 150 mL), then with brine (3 x 150 mL), dried over Na2SO4, filtered, and concentrated under vacuum to give 2-chlorophenanthrene[3,2-b]benzofuran-11-ol 24 (78%, 16.7 g, 52.5 mmol) as a light brown solid.

[0717] Synthesis of Compound 23 of the Invention

[0718]

[0719] Example 23 of the present invention can be synthesized using the scheme described above. The CN coupling reaction of 24 with 3,6-di-tert-butyl-9H-carbazole yields 25, which can be converted to 26 by treatment of 25 with trifluoromethanesulfonic anhydride in the presence of triethylamine, followed by borylation. After the Suzuki coupling of 26 with 2-chloro-4-(2,2-dimethylpropyl-1,1-d2)-5-(methyl-d3)pyridine yields 27, the linkage reaction of compound 27 with dimer 9 produces compound 23 of the present invention as the desired product.

[0720] Synthesis of Compound 24 of the Invention

[0721]

[0722] Example 24 of the present invention can be synthesized via the scheme described above. 24 is reacted with 2-(3,5-diisopropyl-[1,1'-diphenyl]-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane via a Suzuki coupling reaction to yield 28, which can be converted to 29 by treatment with trifluoromethanesulfonic anhydride in the presence of triethylamine followed by Miyaura borylation. After 29 is reacted with 2-chloro-4-(2,2-dimethylpropyl-1,1-d2)-5-(methyl-d3)pyridine via a Suzuki coupling reaction to yield 30, compound 30 is reacted with dimer 9 to produce compound 24 of the present invention as the desired product.

[0723] Synthesis of Compound 25 of the Invention

[0724]

[0725] Example 25 of the present invention can be synthesized via the scheme described above. The Suzuki coupling reaction of 24 with 2-(3,5-di-tert-butylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane yields 31, which can be converted to 32 by treatment with trifluoromethanesulfonic anhydride in the presence of triethylamine followed by Miyaura borylation. After the Suzuki coupling of 32 with 2-chloro-4-(2,2-dimethylpropyl-1,1-d2)-5-(methyl-d3)pyridine yields 33, the linkage reaction of compound 33 with dimer 9 produces compound 25 of the present invention as the desired product.

[0726] Synthesis of Compound 26 of the Invention

[0727]

[0728] Example 26 of the present invention can be synthesized via the scheme described above. 24 is reacted with 2-([1,1':3',1”-terphenyl]-5'-yl)-4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane via a Suzuki coupling reaction to yield 34, which can be converted to 35 by treatment with trifluoromethanesulfonic anhydride in the presence of triethylamine followed by Miyaura borylation. After 35 is reacted with 2-chloro-4-(2,2-dimethylpropyl-1,1-d2)-5-(methyl-d3)pyridine via a Suzuki coupling reaction to yield 36, compound 36 is reacted with dimer 9 to produce compound 26 of the present invention as the desired product.

[0729] Compound characterization

[0730] A variety of compounds of the present invention and comparative compounds were evaluated computationally. Calculations were performed using the B3LYP function with the CEP-31G basis function set. Geometric optimization was performed in vacuum. Excitation energies were obtained for these optimized geometries using time-dependent density functional theory (TDDFT). A continuous solvent model was applied in the TDDFT calculations to simulate tetrahydrofuran solvent. All calculations were performed using the Gaussian program. The calculated values ​​obtained using the DFT functional sets and basis function sets identified above are theoretical values. Synthetic calculation protocols, such as Gaussian16 using the B3LYP and CEP-31G protocols used herein, rely on the assumption that electronic effects are cumulative, and therefore, larger basis function sets can be used to extrapolate to the complete basis function set (CBS) limits. However, when the goal of a study is to understand the variations in HOMO, LUMO, S1, T1, bond dissociation energies, etc., of a range of structure-related compounds, similar cumulative effects are expected. Therefore, although the absolute error introduced by B3LYP may be quite large compared to other calculation methods, the relative differences between the HOMO, LUMO, S1, T1, and bond dissociation energy values ​​calculated using the B3LYP protocol are expected to reproduce experimental results well. See, for example, Hong et al., Chemistry of Materials (Chem. Mater.) 2016, 28, 5791–98, 5792–93 and Supplementary Information (discussing the reliability of DFT calculations in the context of OLED materials). Furthermore, for iridium or platinum complexes applicable to the OLED field, the data obtained from DFT calculations are closely related to actual experimental data. See Tavasli et al., Journal of Materials Chemistry, 2012, 22, 6419–29, 6422 (Table 3) (showing DFT calculations closely correlated with actual data for various emission complexes); Morello, GR, Journal of Molecular Modeling, 2017, 23:174 (studying various DFT functional groups and basis function groups and concluding that the combination of B3LYP and CEP-31G is particularly accurate for emission complexes). The determination of excited-state transition characteristics was performed as a post-processing step on the above DFT and TDDFT calculations. This analysis allows the excited state to be decomposed into holes (i.e., the origin of the excitation) and electrons (i.e., the final position of the excited state). Furthermore, because this analysis is performed on computationally quantifiable properties, it is objective and reproducible; see Mai et al., Coord. Chem. Rev. 2018, 361, 74-97 (discussing the theoretical basis for the excited-state decomposition of transition metal complexes).

[0731] VDR was calculated using density functional theory, including spin-orbit coupling, via transition dipole moments (TDM), and the VDR was calculated as a weighted average of possible TDM orientations. The VDRs of compounds 1 through 22 of the present invention are reported as normalized relative numbers with respect to the results of comparative compound 1; the VDR of compound 23 of the present invention is reported as a normalized relative number with respect to the results of comparative compound 2. Table 1 below shows the T1, S1, HOMO, LUMO, and VDR of the selected compounds.

[0732] Table 1: Energy levels and VDR predictions from DFT calculations

[0733]

[0734]

[0735]

[0736] The calculated data in Table 1 show that the VDR values ​​of the compounds of the present invention are lower than those of applicable comparative compounds. It is believed that the features of the present invention should allow the VDR values ​​to be tuned to a commercially desirable range. EQE is also considered to be directly related to the alignment of the emitter compound. In a family of compounds, more highly aligned emitter compounds are expected to have lower VDR and higher EQE. The relative VDR numbers exhibited by the compounds of the present invention are in the range of 0.526 to 0.816, which are considered to be associated with higher efficiency compared to comparative compounds in commercial OLED devices.

Claims

1. A compound having a first ligand L A The compound comprises the structure of formula I: in: Part A and part D are each independently a monocyclic or fused polycyclic system, wherein each ring in the monocyclic or fused polycyclic system is independently a 5- to 10-membered carbon ring or heterocyclic ring. Some C atoms are 5- or 6-membered carbon rings or heterocycles; Z 1 Z 2 and X 1 To X 4 Each of them is independently C or N; Partial A-bond to X 1 To X 4 One of them, wherein X 1 To X 4 One of them is C; Y is selected from the following groups: BR, BRR', NR, PR, P(O)R, O, S, Se, C=O. C=S, C=Se, C=NR', C=CRR', S=O, SO2, CR, CRR', SiRR' and GeRR'; K is selected from the following groups: direct key, O, S, N(R) α ), P(R α ), B(R) α ), C(R α (R) β ) and Si(R α (R) β ); R A R B R C and R D Each of these terms independently represents a single substitution up to the maximum amount of substitution or no substitution. Each R, R', R α R β R A R B R C and R D Independently, it is hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, boroalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphinyl, selenyl and combinations thereof; At least one R C Or R D It is a substituent R* containing a carbocyclic or heterocyclic group; L A Coordination with metal M; M is selected from the following groups: Ir, Rh, Re, Ru, Os, Pt, Pd, Ag, Au, and Cu; M can coordinate with other ligands; L A It can bind with other ligands to form tridentate, tetradentate, pentadentate or hexadentate ligands; Any two substituents can join or fused to form a ring; and Subject to the following conditions: (1) If part of C is a 6-membered ring and R C Or R D If it is R*, then R* is neither an unsubstituted phenyl nor a phenyl substituted with an electron-withdrawing group; (2) If part of C and part of D together form a naphthalene ring and R C If it is R*, then R * Not unsubstituted carbazole, 2,7-di-tert-butylcarbazole or 3,5-di-tert-butylcarbazole; and (3) If R D If it is R*, then R* is not selected from the list RD defined in this article.

2. The compound according to claim 1, wherein each of portions A and D is independently selected from the group consisting of the following list of cyclic moieties: benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, triazole, cyclopentadiene, selenophene, naphthalene, quinoline, isoquinoline, quinazoline, benzofuran, aza-benzofuran, phenanthro[3,2-b]benzofuran, benzoxazole, aza-benzoxazole, benzothiophene, aza-benzothiophene, benzothiazole, aza-benzothiazole, benzothiazole, aza-benzoxazole, benzothiophene, aza-benzothiphene, benzothiazole, aza-benzothiazole, ... - benzothiazole, benzoselenene, aza-benzoselenene, indene, aza-indene, indole, aza-indole, benzimidazole, aza-benzimidazole, benzobenzimidazole, aza-benzimidazole, carbazole, aza-carbazole, naphthiazole, dibenzofuran, aza-dibenzofuran, dibenzothiophene, aza-dibenzothiophene, quinoxaline, phthalazine, phenanthrene, aza-phenanthrene, anthracene, aza-anthracene, phenanthridine, fluorene, and aza-fluorene; and / or wherein a portion of C is a 6-membered ring; and / or wherein the metal is Ir or Pt; and / or Z 1 It is N, and Z 2 It is C; and / or where X is. 1 To X 4 Each of them is C, or X is one of them. 1 To X 4 At least one of them is N; and / or where Y is selected from the group consisting of: CRR', SiRR', NR, O, S and Se; and / or where K is a direct bond, O or S; and / or where Z 2 Bond to X 1 ; and / or At least one R A Substituents comprising a group selected from the group consisting of: alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof; and / or at least one of the R groups. B Substituents comprising a group selected from the group consisting of: alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof; and / or at least one of the R groups. C Substituents comprising a group selected from the group consisting of: alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof; and / or at least one of the R groups. D The substituent comprises a substituent selected from the group consisting of: alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof; and / or at least one R or R' comprises a substituent selected from the group consisting of: alkyl, cycloalkyl, silalkyl, germanalkyl, aryl, heteroaryl, and combinations thereof; and / or wherein said substituent R* is selected from the group consisting of structures listed in List A below: Wherein (D)H indicates that the part can be H or D.

3. The compound according to claim 1, wherein the two Rs A Joining or fusion to form a ring; and / or two of the R's B Joining or fusion to form a ring; and / or two of the R's C Joining or fused to form a ring; and / or at least two of the R's D Joining or fusion to form a ring.

4. The compound according to claim 1, wherein the at least one R as said substituent R* C Included II The structure, wherein: Ring F is a 5- to 10-membered carbon ring or heterocyclic ring; R F Indicates monosubstituted to trisubstituted or unsubstituted; Each R 1' R 2' and R F Independently, it is hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, boranalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphinyl, selenyl and combinations thereof; and Where R 1' Or R 2' At least one of them is not hydrogen or deuterium.

5. The compound according to claim 1, wherein the at least one R as said substituent R* D Included II The structure, wherein: Ring F is a 5- to 10-membered carbon ring or heterocyclic ring; R F Indicates monosubstituted to trisubstituted or unsubstituted; Each R 1' R 2' and R F Independently, it is hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, boranalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphinyl, selenyl and combinations thereof; and Where R 1' Or R 2' At least one of them is not hydrogen or deuterium.

6. The compound according to claim 1, wherein the ligand L A Select the group consisting of the structures listed in List 1 below: in: X1 to X6 and X8 to X 19 Each can be either C or N independently; Y A Y B and Y C Each of the following groups is selected independently: BR e NR e PR e ,O,S,Se,C=O,S=O,SO2,CR e R f SiR e R f and GeR e R f ; Each R A1 R B1 R B2 and R B3 Independently represents monosubstituted to the maximum possible number of substitutions or no substitution; Each R A1 R B1 R B2 R B3 R e and R f Substituents that are independently hydrogen or selected from the group of universal substituents as defined herein; Any two substituents can join or fused to form a ring; and At least one R B2 Or R B3 It is a substituent R* that contains a carbocyclic group or a heterocyclic group.

7. The compound according to claim 1, wherein the ligand L A Select the group consisting of the structures listed in List 2 below: in: X is C or N; Y A Y B and Y C Each of the following groups is selected independently: BR e NR e PR e ,O,S,Se,C=O,S=O,SO2,CR e R f SiR e R f and GeR e R f ; Each R A1 R B1 R B2 and R B3 Independently represents monosubstituted to the maximum possible number of substitutions or no substitution; Each R A1 R B1 R B2 R B3 R e and R f Substituents that are independently hydrogen or selected from the group of universal substituents as defined herein; Any two substituents can join or fused to form a ring; and At least one R B2 Or R B3 It is a substituent R* that contains a carbocyclic group or a heterocyclic group.

8. The compound according to claim 1, wherein the ligand L A Selected from L Ai (R H (R) I (R) J (R) K (R) L L Ai' (R H (R) I (R) J (R) K' (R) L L Ai” (R H (R) I (R) J (R) K” (R) L L A'n (R H (R) I (R) J (R) K (R) L ) and L A'n' (R H (R) I (R) J (R) K (R) K” (R) L ), where i is an integer from 1 to 11, i' is an integer from 12 to 37, i” is an integer from 38 to 43, n is an integer from 1 to 12, n' is an integer from 13 to 26, and R H R I R J and R K Each of these is independently selected from V1 to V192; R L Selected from O1 to O328; R K' Selected from V1 to V180; R K” Selected from V1 to V178; and L Ai (R H (R) I (R) J (R) K (R) L L Ai' (R H (R) I (R) J (R) K' (R) L ) and L Ai” (R H (R) I (R) J (R) K” (R) L Each of the following is defined in Listing 3: Where L A'n (R H (R) I (R) J (R) K (R) L ) and L A'n' (R H (R) I (R) J (R) K (R) K” (R) L () is defined in the following listing 3a: Where O1 to O328 are defined in Listing A as defined herein; and V1 to V192 are defined in the following Listing B:

9. The compound according to claim 1, wherein the compound has M(L) A ) p (L B ) q (L C ) r The formula, where L B and L C Each is a bidentate ligand; and p is 1, 2 or 3; q is 0, 1 or 2; r is 0, 1 or 2; and p+q+r is the oxidation state of the metal M.

10. The compound according to claim 9, wherein the compound has a composition selected from Ir(L A 3. Ir(L) A (L) B )2、Ir(L A )2(L B ), Ir(L A )2(L C ) and Ir(L A (L) B (L) C The expression consisting of a group of ) and where L A L B and L C They are different from each other; or Pt(L) A (L) B The formula is: ) and where L A and L B They can be the same or different.

11. The compound according to claim 9, wherein L B and L C Each group is independently selected from the following groups, which are composed of structures listed in List 4: in: T can be freely selected from the following groups: B, Al, Ga, and In; K 1' Choose from the following groups: single bond, O, S, NR e PR e BR e CR e R f and SiR e R f ; Y 1 To Y 13 Each of them is independently selected from the group consisting of C and N; Y' selects from the following groups: BR e BR e R f NR e PR e P(O)R e ,O,S,Se,C=O,C=S,C=Se,C=NR e C = CR e R f S = O, SO2, CR e R f SiR e R f and GeR e R f ; R e and R f They can be fused or joined to form rings; Each R a R b R c and R d Independently represents single substitution up to the maximum permissible number of substitutions or no substitution; R a1 R b1 R c1 R d1 R a R b R c R d R e and R f Each of these groups is independently hydrogen or a substituent selected from the group consisting of: deuterium, halogroup, alkyl, cycloalkyl, heteroalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, boranalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ester, nitrile, isonitrile, thio, selenalkyl, sulfinyl, sulfonyl, phosphinyl, and combinations thereof; and R a1 R b1 R c1 R d1 R a R b R c and R d Any two substituents can fused or joined to form a ring or a polydentate ligand.

12. The compound according to claim 9, wherein the compound has the formula Ir(L A 3. Formula Ir(L) A (L) Bk )2. Equation Ir(L A )2(L Bk ), formula Ir(L A )2(L Cj-I ) or formula Ir(L A )2(L Cj-II ), Where L A It is based on formula I; Where k is an integer from 1 to 543, and Each L Bk It has a structure as defined in Listing 6 below: Each L Cj-I With a based The structure; and Each L Cj-II With a based The structure, where for L Cj-I and L Cj-II Each L in Cj R 201 and R 202 Each is defined independently as shown in Listing 7 below: and Where R D1 To R D246 It has the structure defined in Listing C below:

13. The compound of claim 1, wherein the compound is selected from the group consisting of structures listed in List 9:

14. An organic light-emitting device (OLED) comprising: anode; cathode; and An organic layer disposed between the anode and the cathode, wherein the organic layer comprises an organic layer having a first ligand L A A compound comprising the structure of formula I: in: Part A and part D are each independently a monocyclic or fused polycyclic system, wherein each ring in the monocyclic or fused polycyclic system is independently a 5- to 10-membered carbon ring or heterocyclic ring. Some C atoms are 5- or 6-membered carbon rings or heterocycles; Z 1 Z 2 and X 1 To X 4 Each of them is independently C or N; Partial A-bond to X 1 To X 4 One of them, wherein X 1 To X 4 One of them is C; Y is selected from the following groups: BR, BRR', NR, PR, P(O)R, O, S, Se, C=O, C=S, C=Se, C=NR', C=CRR', S=O, SO2, CR, CRR', SiRR' and GeRR'; K is selected from the following groups: direct key, O, S, N(R) α ), P(R α ), B(R) α ), C(R α (R) β ) and Si(R α (R) β ); R A R B R C and R D Each of these terms independently represents a single substitution up to the maximum amount of substitution or no substitution. Each R, R', R α R β R A R B R C and R D Independently, it is hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, boroalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphinyl, selenyl and combinations thereof; At least one R C Or R D It is a substituent R* containing a carbocyclic or heterocyclic group; L A Coordination with metal M; M is selected from the following groups: Ir, Rh, Re, Ru, Os, Pt, Pd, Ag, Au, and Cu; M can coordinate with other ligands; L A It can bind with other ligands to form tridentate, tetradentate, pentadentate or hexadentate ligands; Any two substituents can join or fused to form a ring; and Subject to the following conditions: (1) If part of C is a 6-membered ring and R C Or R D If it is R*, then R* is neither an unsubstituted phenyl nor a phenyl substituted with an electron-withdrawing group; (2) If part of C and part of D together form a naphthalene ring and R C If it is R*, then R * Not unsubstituted carbazole, 2,7-di-tert-butylcarbazole or 3,5-di-tert-butylcarbazole; and (3) If R D If it is R*, then R* is not selected from the list RD defined in this article.

15. A consumer product including an organic light-emitting device (OLED), said OLED comprising: anode; cathode; and An organic layer disposed between the anode and the cathode, wherein the organic layer comprises an organic layer having a first ligand L A A compound comprising the structure of formula I: in: Part A and part D are each independently a monocyclic or fused polycyclic system, wherein each ring in the monocyclic or fused polycyclic system is independently a 5- to 10-membered carbon ring or heterocyclic ring. Some C atoms are 5- or 6-membered carbon rings or heterocycles; Z 1 Z 2 and X 1 To X 4 Each of them is independently C or N; Partial A-bond to X 1 To X 4 One of them, wherein X 1 To X 4 One of them is C; Y is selected from the following groups: BR, BRR', NR, PR, P(O)R, O, S, Se, C=O, C=S, C=Se, C=NR', C=CRR', S=O, SO2, CR, CRR', SiRR' and GeRR'; K is selected from the following groups: direct key, O, S, N(R) α ), P(R α ), B(R) α ), C(R α (R) β ) and Si(R α (R) β ); R A R B R C and R D Each of these terms independently represents a single substitution up to the maximum amount of substitution or no substitution. Each R, R', R α R β R A R B R C and R D Independently, it is hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, boroalkyl, aralkyl, alkoxy, aryloxy, amino, silalkyl, germanalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphinyl, selenyl and combinations thereof; At least one R C Or R D It is a substituent R* containing a carbocyclic or heterocyclic group; L A Coordination with metal M; M is selected from the following groups: Ir, Rh, Re, Ru, Os, Pt, Pd, Ag, Au, and Cu; M can coordinate with other ligands; L A It can bind with other ligands to form tridentate, tetradentate, pentadentate or hexadentate ligands; Any two substituents can join or fused to form a ring; and Subject to the following conditions: (1) If part of C is a 6-membered ring and R C Or R D If it is R*, then R* is neither an unsubstituted phenyl nor a phenyl substituted with an electron-withdrawing group; (2) If part of C and part of D together form a naphthalene ring and R C If it is R*, then R * Not unsubstituted carbazole, 2,7-di-tert-butylcarbazole or 3,5-di-tert-butylcarbazole; and (3) If R D If it is R*, then R* is not selected from the list RD defined in this article.

Images